ANALYSIS OF ADP RECEPTOR SIGNALING PATHWAYS IN NOCICEPTORS AND IMPLICATIONS FOR INFLAMMATORY PAIN by Shah, Mansi
ANALYSIS OF ADP RECEPTOR SIGNALING PATHWAYS IN NOCICEPTORS AND 
IMPLICATIONS FOR INFLAMMATORY PAIN 
by 
Mansi Ashish Shah 
B.S. Neuroscience, University of Pittsburgh, 2010 
Submitted to the Graduate Faculty of the 
School of Medicine in partial fulfillment 
of the requirements for the degree of 
PhD in Neurobiology 
University of Pittsburgh 
2016 
ii 
UNIVERSITY OF PITTSBURGH 
SCHOOL OF MEDICINE 
This dissertation was presented 
by 
Mansi Ashish Shah 
It was ded on 
February 18, 2016 
and approved by 
 Gerald F. Gebhart, Ph.D., Professor 
Kathryn M. Albers, Ph.D., Professor 
Brian M. Davis, Ph.D., Professor 
Sarah E. Ross, Ph.D., Assistant Professor 
Julie A. Christianson, Ph.D., Assistant Professor 
Dissertation Advisor: Derek. C. Molliver, Ph.D., Associate Professor 
 
CHARACTERIZATION OF ADP RECEPTORS AND THEIR SIGNALING IN 
NOCICEPTORS 
Mansi Ashish Shah, PhD 
University of Pittsburgh, 2016 
 Chronic pain afflicts more than 100 million Americans and significantly affects the quality of life 
of those suffering. Opioid receptor agonists are effective analgesics but have severe dose-limiting 
side effects and display drug tolerance with prolonged use. Understanding key pathways that 
modulate pain is critical to developing analgesics that are more effective. In my dissertation, I 
investigated the importance of three key purinergic receptor signaling pathways in nociception: 
P2Y1, P2Y12 and P2Y13. Purinergic receptors respond to nucleotides released from damaged 
tissue and/or immune cells and have long been implicated in modifying nociceptive responses, 
however, the P2Y G-protein coupled purinergic receptor family is just starting to be investigated.  
P2Y1, P2Y12 and P2Y13 receptors are activated by the nucleotide adenosine diphosphate 
(ADP), however,  the receptors have opposing effects because the P2Y1 receptor is Gq/11-coupled, 
whereas the P2Y12 and P2Y13 receptors are Gi/o-coupled. Traditionally, Gq-coupled receptors are 
pro-nociceptive while Gi/o-coupled receptors are anti-nociceptive. In order to understand the 
implications of antagonistic signaling between the P2Y1 and P2Y12/P2Y13 receptors during 
inflammatory pain, the signaling cascades for each individual receptor must first be elucidated. 
For the first part of my dissertation, I tested the hypothesis that P2Y1 Gq-coupled receptors 
signal through conventional protein kinase C isoforms (cPKC) and that these isoforms mediate the 
behavioral effects of P2Y1 receptor activation. I discovered that the cPKC isoform PKCα is 
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expressed predominately in the IB4+ population, similar to the P2Y1 receptor, and that antagonism 
of PKCα attenuates P2Y1 receptor-mediated mechanical hypersensitivity. These results 
demonstrate the importance of cPKCs in the P2Y1 signaling cascade and detail how P2Y1 
receptors function. Next, I tested the hypothesis that P2Y12/P2Y13 Gi/o-coupled signaling is 
important for maintaining basal nociceptive tone and modulating pro-nociceptive signaling. I 
discovered that all three ADP-activated receptors, P2Y1, P2Y12 and P2Y13, are active at baseline 
and likely maintain basal nociceptive tone. Additionally, P2Y12 and P2Y13 receptors are capable 
of attenuating signaling through pro-inflammatory Gs-coupled pathways, validating the 
importance of P2Y12 and P2Y13 receptors as potential analgesics.  
These results provide insight into the signaling cascades of P2Y1, P2Y12 and P2Y13 
receptors and advance our understanding of nociceptive signaling. 
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1.0  GENERAL INTRODUCTION 
1.1 INFLAMMATORY PAIN IN HUMANS, MOUSE MODELS AND ROLE OF THE 
PURINERGIC SYSTEM 
Pain results from a wide array of conditions, from tissue damage to idiopathic diseases to nerve 
damage. Staggeringly, over 100 million Americans are thought to suffer from chronic pain  (2011). 
Pain sufferers face significant impediments to their physical and psychological well-being, which 
produces a substantial barrier to overall quality of life. The economic burden that results from lost 
productivity, along with the immense strain placed on the healthcare system, all contribute to pain 
being a serious public health issue.  
Persistent inflammation can produce prolonged and often intractable pain. Clinical features 
of inflammation include edema, erythema and pain at the affected site. A vast number of disorders, 
with substantially different underlying pathologies, such as cancers, rheumatoid arthritis and 
interstitial cystitis, have inflammatory components that contribute to producing pain. 
Inflammatory pain results from the release of a variety of pro-inflammatory molecules from 
damaged tissue and immune cells; this released “inflammatory soup” is responsible for activating 
a wide array of G-protein coupled receptors (GPCRs), ion channels, transcription factors and pro-
inflammatory signaling cascades in nociceptors innervating the periphery (Waxman et al., 1999, 
Kidd and Urban, 2001, Tominaga and Caterina, 2004, Obata and Noguchi, 2006, Hucho and 
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Levine, 2007, Deval et al., 2010, Schaible et al., 2010). Once the nociceptors are active, the signal 
is sent to the spinal cord and brain where central mechanisms of nociception and pain signaling 
become involved. Sensitization of the nociceptive signaling components is critical for potentiating 
the inflammatory response. Cellular sensitization is characterized by modulation of receptor/ion 
channel numbers via transcription or translation, changes in gating properties of ion channels and 
increased presence of pro-algesic agents such as prostaglandins (Costigan and Woolf, 2000, Julius 
and Basbaum, 2001, Basbaum et al., 2009, Latremoliere and Woolf, 2009, Ji et al., 2014). 
In order to model human inflammatory pain conditions, several inflammatory agents are 
used in mouse models. The complete Freund’s adjuvant (CFA) model is well characterized and 
commonly used in rodents. CFA is a solution of inactivated mycobacteria, which when injected 
subcutaneously produces a hallmark inflammatory response that generates edema, sensitization of 
the injected site as well as recruitment of immune cells to the area (Billiau and Matthys, 2001, 
Gauldie et al., 2004, Lin et al., 2007, Barrot, 2012, Li et al., 2013). The CFA model is considered 
to be a chronic inflammatory assay as a single dose of CFA into mouse hindpaw, a common site 
to inject for peripheral pain assays, produces hypersensitivity that peaks at three days post-
injection and lasts as long as two weeks (Ren and Dubner, 1999). 
A hallmark of inflammation is the release of adenosine triphosphate (ATP) from damaged 
tissue and immune cells. The endogenous receptors for the released ATP and ATP metabolites are 
the purinergic receptors, which were first discovered in the 1970s (Burnstock, 2006, Burnstock, 
2012). Purinergic receptors are expressed broadly in rodents, and importantly for inflammatory 
pain, they are expressed in immune cells and nociceptors (Dussor et al., Burnstock, 2001a, 
Burnstock, 2007, Dussor et al., 2009, Magni and Ceruti, 2014). The purinergic receptor family is 
broken into two large subfamilies, consisting of the ionotropic P2X and the metabotropic P2Y 
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receptors. While the ionotropic P2X receptor subfamily has been extensively investigated for its 
role in peripheral inflammatory pain (Bland-Ward and Humphrey, 1997, Toulme E, 2010), there 
is considerably less literature on the metabotropic P2Y receptors. The P2Y receptor family is 
particularly interesting as the family contains receptors conjugated to both pro-nociceptive and 
anti-nociceptive G-protein coupled signaling cascades. For example, the P2Y1 and P2Y2 receptors 
are pro-nociceptive following CFA-induced hindpaw inflammation whereas P2Y12, P2Y13 and 
P2Y14 have anti-nociceptive effects when activated in the same model (Malin and Molliver, 
2010). The diversity of effects following P2Y receptor activation makes this family especially 
fascinating, as P2Y family members can be selected that enhance anti-nociceptive effects or reduce 
pro-nociceptive effects during inflammation for the development of effective analgesics.  
1.2 THE IMPORTANCE OF PURINERGIC P2Y SIGNALING 
Nucleotide release is one of the trademarks of inflammatory pain, with damaged tissue and 
immune cells the primary source. Nucleotides activate the purinergic family of receptors, and this 
activation is critical for the inflammatory response (Beamer et al., Malin and Molliver, 2010, 
Molliver et al., 2011, Eltzschig et al., 2012, Idzko et al., 2014, Di Virgilio and Vuerich, 2015). 
Interestingly, nucleotide release has also been shown to occur in non-inflammatory basal states 
implying that purinergic receptors might also have some degree of tonic activity (Donaldson et al., 
2000, Lazarowski et al., 2000). Therefore, purinergic receptors could play a key role in establishing 
basal nociceptive tone as well as modulating the inflammatory response.  
The sole nucleotide released from tissues and immune cells is ATP; however, enzymes 
present on axon terminals metabolize ATP into a variety of active metabolites such as ADP 
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(Figure 1). The enzymes responsible for metabolizing ATP are called ecto-nucleoside 
triphosphate diphosphohydrolases (NTPDases), and they comprise a large family present on axon 
terminals and broadly in the brain (Vorhoff et al., 2005, Robson et al., 2006). Of the NTPDases 
present in cells, four family members are located on the cell-surface (NTPDase 1, 2, 3 and 8), and 
these specifically are responsible for metabolizing extracellular released ATP into other signaling 
nucleotides (Robson et al., 2006). The efficacy of ATP hydrolysis varies based on the NTPDase 
in question, and each of the four membrane-bound NTPDases produce specific nucleotide products 
(Kukulski et al., 2005). Thus, the sensitivity of the system to ATP relies heavily on the NTPDases, 
as it is possible that small, tonic release of ATP is likely to be immediately broken down into ADP 
and other metabolites, whereas in an inflammatory condition where there is substantial increase in 
released ATP, ATP lingers longer. Therefore, the activation of P2Y1, P2Y12 and P2Y13 receptors 
depends on presence of specific NTPDase family members on nociceptors and the state of the 
system itself (i.e. inflamed versus baseline).  
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Figure 1: ATP release and metabolism. Cell-surface bound ecto-nucleoside triphosphate 
diphosphohydrolases (NTPDases) break down ATP into several key active metabolites, ADP, 
AMP and adenosine. Of the larger family of NTPDases, four are cell-surface bound: NTPDase1, 
NTPDase2, NTPDase3 and NTPDase8. mRNA for these NTPDases is detected in dorsal root 
ganglia, with NTPDase3 protein detected in the dorsal root ganglion neurons as well. Image from 
Vongtau et al. 2011 (Vongtau et al., 2011a). 
 
 Work from our laboratory demonstrated that NTPDase1-3 mRNAs are present in mouse 
dorsal root ganglion and spinal cord, and immunohistochemical staining showed that NTPDase3 
was present on dorsal root ganglion neurons themselves (Vongtau et al., 2011a). NTPDase3 
produces ADP and is a source of ATP to ADP hydrolysis (Vongtau et al., 2011a). Thus, 
nociceptors in the dorsal root ganglion contain the necessary enzymes to produce ADP and activate 
P2Y1, P2Y12 and P2Y13 receptors. NTPdase3 is present in peripheral cutaneous nociceptors 
projecting to the glabrous hindpaw, indicating peripheral afferents also contain the necessary 
enzymes to produce ADP (Vongtau et al., 2011f). 
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The purinergic P2Y receptor family consists of receptors conjugated to the three commonly 
studied Gα subunits, Gαs, Gαq/11 and Gαi/o (Table 1). The binding of  agonists to GPCRs leads to 
dissociation of the G-protein complex, which is formed by the Gα  and Gβγ subunits. The 
Gα subunit is the key determinant of the receptor response by virtue of the three canonical Gα 
subunits: Gαq, Gαs and Gαi/o. Receptors conjugated to Gαq or Gαs subunits predominately have pro-
nociceptive effects, while receptors conjugated to the Gαi/o subunit have anti-nociceptive effects 
(Figure 2) (Bailey and Connor, 2005, DuPen et al., 2007, Pan et al., 2008). Opioids, for example, 
are conjugated to Gαi/o subunits and are powerful analgesics whereas subsets of the strongly pro-
algesic prostaglandins signal through Gαs subunits (Sora et al., 1997, Loh et al., 1998, Bailey and 
Connor, 2005, Lin et al., 2006, Ricciotti and FitzGerald, 2011, St-Jacques and Ma, 2014). 
Studies have implicated each of the eight G-protein coupled P2Y receptor family members 
in pain signaling, further demonstrating the importance of purinergic pathways in nociception 
(Molliver et al., 2002, Stucky et al., 2004, Malin et al., 2008, Malin and Molliver, 2010, Molliver 
et al., 2011, Jankowski et al., 2012, Barragán-Iglesias et al., 2015). While each of the P2Y receptors 
are activated by a specific nucleotide, the P2Y1, P2Y12 and P2Y13 receptors are unique in that all 
are activated by the nucleotide adenosine diphosphate (ADP) (Table 1). Despite all three of these 
receptors responding to ADP, their downstream effects are actually opposing as P2Y1 is 
conjugated to the Gαq subunit while P2Y12 and P2Y13 are conjugated to the Gαi/o subunits (Figure 
2). 
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P2Y 
receptor Agonist G-Protein 
Expression in 
relevant 
nociceptive 
machinery 
References 
P2Y1 ADP Gαq 
Dorsal root 
ganglia (primarily 
IB4+ neurons), 
CNS microglia, 
peripheral 
immune cells 
(Bowler et al., 2003, Crain 
et al., 2009, Malin and 
Molliver, 2010, Molliver et 
al., 2011) 
P2Y2 ATP/UTP Gαq 
  P2Y4 UTP Gαq and Gαi P2Y6 UDP Gαq 
P2Y11 ATP Gαs and Gαq 
P2Y12 ADP Gαi/o 
Dorsal root 
ganglia (small 
diameter 
neurons), CNS 
microglia, 
peripheral 
immune cells 
(Haynes et al., 2006, 
Visentin et al., 2006, 
Tozaki-Saitoh et al., 2008, 
Crain et al., 2009, Malin 
and Molliver, 2010, Jacob et 
al., 2013) 
P2Y13 ADP Gαi/o 
Dorsal root 
ganglia (small and 
large diameter 
neurons), CNS 
microglia, 
peripheral 
immune cells 
(Crain et al., 2009, Malin 
and Molliver, 2010, Jacob et 
al., 2013) 
P2Y14 UDP-sugars Gαi/o   
 
Table 1: Expression of P2Y purinergic receptors. P2Y1, P2Y12 and P2Y13 are all present in 
small diameter dorsal root ganglion neurons, with P2Y1 primarily expressed in the nonpeptidergic 
IB4+ subpopulation (Borvendeg et al., 2003, Moriyama et al., 2003, Molliver et al., 2011). All 
three receptors are present on a variety of immune cells in the periphery, as well as microglia in 
the central nervous system (Jacob et al., 2013). 
 
The significance of ADP activating both Gq- and Gi/o-coupled receptors is that both pro-
nociceptive (via P2Y1 Gq-coupled receptor) and anti-nociceptive drives (via P2Y12 and P2Y13 
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Gi/o-coupled receptors) are simultaneously active in inflammatory states. Work from our 
laboratory has implicated the P2Y1 receptor as crucial for the full presentation of thermal 
hyperalgesia in CFA-induced inflammation and the P2Y12/P2Y13 receptors for dampening 
excitatory drive in nociceptors (Malin and Molliver, 2010); however, there is still a severe lack of 
information in the pain literature regarding the components that make up these receptors’ signaling 
cascades.  
The majority of information regarding P2Y1/P2Y12/P2Y13 receptor signaling cascades 
comes from work in cell lines or other cell systems, which while informative does not fully capture 
the complex and context-dependent nature of GPCR signaling in neurons (Czajkowski et al., 2004, 
Van Kolen and Slegers, 2004, Wirkner et al., 2004, Quinton et al., 2005, Soulet et al., 2005, May 
et al., 2006, Srinivasan et al., 2009, Iyú et al., 2011, Lyubchenko et al., 2011, Zeng et al., 2014, 
Yang et al., 2015). 
The information presented in the remainder of this chapter aims to explain the function and 
importance of P2Y1, P2Y12 and P2Y13 receptors and highlight their potential as treatments for 
inflammatory pain. 
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Figure 2: Purinergic P2Y1, P2Y12 and P2Y13 receptor signaling. Adenosine diphosphate 
(ADP) activates the pro-nociceptive P2Y1 Gq-coupled receptor and the Gi/o-coupled anti-
nociceptive P2Y12 and P2Y13 receptors. A key downstream effector for P2Y1 receptors signaling 
is protein kinase C (PKC), which modulates proteins via phosphorylation. P2Y12 and P2Y13 
receptors prevent cAMP production and as a result, block activation of protein kinase A (PKA), 
the downstream effector for Gs-coupled signaling. Similar to PKC, PKA has been demonstrated to 
modify key proteins involved in inflammation via phosphorylation. All three ADP-activated 
purinergic receptors are implicated in inflammatory pain.  
1.3 THE P2Y1 RECEPTOR: SIGNALING, FUNCTION, AND EXPRESSION 
The P2Y1 receptor is part of a large family of nucleotide-activated G-protein coupled purinergic 
P2Y receptors. In humans, eight P2Y purinergic receptors have been cloned thus far and each are 
encoded by distinct genes (von Kügelgen and Hoffmann, von Kügelgen, 2006). As GPCRs, the 
P2Y family of receptors are seven transmembrane helical proteins, with extracellular N-termini 
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for ligand binding and intracellular C-termini that facilitate intracellular signaling. These receptors 
show broad expression in tissue and immune cells, and all of the P2Y receptors, with the exception 
of P2Y4, have been directly implicated in nociceptive processes (von Kügelgen and Hoffmann, 
Mohanty et al., 2001, Stucky et al., 2004, del Rey et al., 2006, Malin et al., 2008, Myrtek et al., 
2008, Malin and Molliver, 2010, Gao et al., 2013, Barragan-Iglesias et al., 2014, Burnstock and 
Boeynaems, 2014, Barragán-Iglesias et al., 2015). 
The P2Y1 purinergic receptor is activated by the nucleotide adenosine diphosphate (ADP).  
The binding of ADP on the N-terminus of the P2Y1 receptor leads to a dissociation of the Gαq and 
Gβγ subunits from the C-terminus (Figure 2). The Gαq subunit then activates phospholipase C 
(PLC), which in turn leads to the production of diacylglycerol (DAG) and inositol triphosphate 
(IP3). Both DAG and IP3 are important for activating the key downstream effector of P2Y1 
signaling, protein kinase C (PKC); DAG binds directly to PKCs whereas IP3 leads to internal store 
calcium release that is necessary for PKC activation. Once activated, PKCs can alter cell 
excitability via phosphorylation and subsequent sensitization of membrane ion channels, modify 
membrane ion channel expression levels, regulate transcription and produce a variety of cell-type 
specific modulatory effects (Abe et al., Newton, 1995, Bhave et al., 2003, Ferreira et al., 2005, Lee 
et al., 2008, Srinivasan et al., 2008, Cang et al., 2009, Mandadi et al., 2011a, Zhang et al., 2011). 
Thus, activation of the P2Y1 receptor can have drastic effects on cellular function, both acutely 
and chronically. 
In cell types involved with peripheral nociception, such as nociceptors, keratinocytes and 
immune cells, the P2Y1 receptor is strongly expressed. Specifically, the immune cells that have 
been directly implicated in peripheral inflammatory pain, such as macrophages, show P2Y1 
receptor expression (Bowler et al., 2003, Basbaum et al., 2009, Jacob et al., 2013, Burnstock and 
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Boeynaems, 2014). Interestingly, work from our laboratory and several other groups have 
demonstrated that P2Y1 is primarily found in the IB4-binding nonpeptidergic subpopulation of 
nociceptors (Borvendeg et al., 2003, Moriyama et al., 2003, Molliver et al., 2011). The significance 
of this selective expression is that the nonpeptidergic, IB4+ population is critical for the full 
presentation of mechanical and thermal hyperalgesia in inflammation (Vulchanova et al., 2001, 
Tarpley et al., 2004, Breese et al., 2005, Alvarez et al., 2012). Importantly, P2Y1 expression within 
these cells is critical for the full presentation of inflammatory pain and for normal thermal 
sensitivity (Malin and Molliver, 2010, Molliver et al., 2011).  
1.3.1 P2Y1 receptor signaling and role in inflammatory pain 
Unlike the extensively studied ionotropic purinergic family members, there are limited studies 
looking at the G-protein coupled P2Y family, and more specifically at the P2Y1 receptor in 
nociceptors. Work from our laboratory has demonstrated the importance of P2Y1 in the 
maintenance of inflammatory pain (Malin and Molliver, 2010). Specifically, in the complete 
Freund’s adjuvant (CFA) model of inflammation, P2Y1 knockout mice (P2Y1KO) displayed a 
longer withdrawal latency to a radiant heat source at 3 days post-CFA hindpaw injection compared 
to wildtype (WT) mice. Additionally, P2Y1 antagonism in WT mice with CFA-induced 
inflammation produces a temporary reversal in heat hyperalgesia. These results suggest that a lack 
of peripheral P2Y1 receptors during peripheral inflammation attenuates the thermal hyperalgesia 
normally seen with CFA, implicating the P2Y1 receptor in the maintenance of the inflammatory 
state. P2Y1 expression is also increased following CFA administration into the hindpaw, 
suggesting that the increased P2Y1 expression helps maintain or promote inflammation 
(Jankowski et al., 2012). IB4+ c-polymodal nociceptors (CPMs) failed to sensitize to noxious heat 
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in response to CFA-induced inflammation when P2Y1 expression was knocked down, providing 
a potential mechanism by which the P2Y1 receptor contributes to inflammatory pathology 
(Jankowski et al., 2012). Basal thermal thresholds of identified afferents are also affected by P2Y1, 
with P2Y1KO mice demonstrating an increase in mean heat thresholds in response to a thermal 
ramp (Molliver et al., 2011). Taken together, these studies demonstrate a clear role for P2Y1 in 
the peripheral inflammatory process in mice.  
The vast majority of work on the P2Y1 receptor focuses on the global effects of P2Y1 
receptor activation on cell excitability or behavior, and very few studies exist in the pain literature 
that directly investigate P2Y1 receptor signaling cascades. While the results of published studies 
hint at potential mechanisms of action, very few studies offer direct insight into P2Y1 receptor 
signaling and its components in nociceptors. The importance of investigating P2Y1 signaling 
specifically within nociceptors is supported by work from other model systems that indicate that 
there are context-dependent (i.e. during inflammation versus basal states) and cell type-specific 
differences in the components that make up the P2Y1 signaling cascade. For example, in platelet 
literature where most of the work on P2Y1 receptors has been conducted, PKCs actually contribute 
to P2Y1 receptor desensitization, which is in contrast to the traditional view of PKCs solely being 
downstream effectors (Mundell et al., 2006a, Barton et al., 2008). Furthermore, specific PKC 
isoforms within the larger PKC family are involved in P2Y1 receptor desensitization, with the 
classical PKCs and PKCδ implicated (Mundell et al., 2006a). The variation in which signaling 
components P2Y1 signals through is not surprising given that there are clear differences in what 
components are expressed in different cell-types. In dorsal root ganglia neurons, for example, 
certain family members of the downstream P2Y1 receptor effector, PKC, are expressed broadly 
whereas others show selective expression in nociceptor subpopulations (see Allen Brain Atlas, 
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(Usoskin et al., 2015)). PKCδ is present in peptidergic and nonpeptidergic populations whereas 
the classical PKC family member PKCβ is in large myelinated and peptidergic populations 
(Usoskin et al., 2015). The selective expression of PKC family members in nociceptors has 
implications for what effects P2Y1 activation has, as P2Y1 receptors are predominately in the 
nonpeptidergic population. Therefore, in order to fully understand the effects of P2Y1 activation 
in nociceptors and during inflammation, the expression and function of PKCs in the same 
population must also be known.  
1.3.2 Protein kinase C (PKC) structure, function and role in inflammatory pain 
A major downstream effector for Gq-coupled receptors, such as P2Y1, is protein kinase C (PKC). 
Protein kinase C is an enzyme that phosphorylates proteins, resulting in modulation of protein 
function. The PKC family of enzymes targets proteins on specific sequences flanked by 
serine/threonine residues, with different PKC isoforms showing preference for different flanking 
sequences (Nishikawa et al., 1997). The protein kinase C family is subdivided into three large 
subfamilies, conventional, novel and atypical, and each isoform within the subfamilies is encoded 
by a separate gene (Steinberg, 2008). The conventional PKC (cPKC) members consist of isoforms 
PKCα, PKCβI and PKCβII and PKCγ and this family is defined by its requirement of both calcium 
and diacylglycerol (DAG) to activate. Novel PKC (nPKC) family members include PKCδ, PKCε, 
PKCθ and PKCη and this family requires DAG but not calcium for activation. Finally, the atypical 
PKCs (aPKC), comprised of PKCMζ and PKCι/λ isoforms, do not require DAG or calcium for 
activation. In all three subfamilies of PKCs, the general structure of the enzyme is similar; PKCs 
contain a regulatory domain, where the DAG and/or calcium binding domains are located, and a 
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catalytic domain that is responsible for phosphorylating targets (Figure 3). The difference between 
the three families lies primarily in the regulatory domain (Mochly-Rosen et al., 2012). 
In the native state, PKCs are thought to be in confirmation that renders their catalytic 
domain inactive. This inactive state is achieved due to the pseudo substrate domain (PS), which 
provides a binding site for the catalytic domain so that it cannot phosphorylate other targets 
(Steinberg, 2008). The pseudo substrate domain has a similar sequence to the substrates targeted 
by PKC, and this similarity allows for PKC auto-inhibition. Once the appropriate molecules-such 
as calcium- are present to bind to the regulatory domain, the PKC can translocate to the membrane 
and bind DAG. The translocation of PKC to the membrane is dependent on the N-terminal 
phosphatidylserine binding site, which allows PKC to be attracted to the membrane and translocate 
when the site is exposed (Stahelin et al., 2005). The binding of PKC to the membrane via the 
phosphatidylserine domain sterically frees the regulatory domain from the catalytic domain, 
allowing the exposed catalytic site to phosphorylate target proteins (Kazanietz and Lemmon, 2011, 
Leonard et al., 2011). 
15 
Figure 3: Protein kinase (PKC) structure. The Protein kinase C family is divided into 3 main 
groups: conventional (cPKC), novel (nPKC) and atypical (aPKC). cPKCs contain calcium and 
diacylglycerol (DAG) binding sites in the regulatory domain, either of which can activate cPKCs. 
nPKCs only require DAG to activate and contain a catalytic domain very similar to cPKCs. The 
sequences of cPKCs and nPKCs are highly homologous, whereas aPKCs do not share the high 
sequence homology and are activated by different second messengers (Mochly-Rosen et al., 2012). 
The pseudo substrate domain (PS domain) provides a binding site for the catalytic domain such 
that at basal states, PKCs are in an inactive state (autoinhibition). 
The kinetics of PKC activation/inactivation are quite complex, with the cellular 
environment determining which PKC isoforms are involved and how they function. Differences 
in cellular environment could be due to (1) manipulation of PKC isoforms themselves by 
overexpression, (2) variation in PKC isoform expression between different cell types, (3) 
presence/absence of chaperone and/or adapter proteins and (4) presence of inflammatory or 
“stressful” stimuli. These differences are intertwined, as work with PKCs traditionally relies on 
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transfecting in the specific PKC isoform and studying function (Khasar et al., 1999, Sakaue et al., 
2003, Kang et al., 2010, Zhang et al., 2011). Thus, in many studies, all four of the differences 
highlighted above are present, which hinders understanding of how PKCs actually function in 
biologically relevant situations. These differences can drastically alter the outcome of GPCR-
mediated signaling, an effect that is underscored by studies in both cell lines and primary cells 
(Hucho et al., 2005, Summer et al., 2006, He and Wang, 2015).  
Activation of PKCs, particularly the conventional and novel families, leads to translocation 
of the PKCs to the membrane (Cesare et al., 1999, Hucho et al., 2005, Mandadi et al., 2011d, He 
and Wang, 2015). The translocation event is generally considered a hallmark of PKC activation, 
and consequently most studies use translocation and activation synonymously. Because the most 
studied targets of PKC activation in the pain literature are membrane ion channels, it is reasonable 
to assume that for PKC to have effects on ion channels, translocation to the membrane is necessary. 
However, what this line of thinking does not account for is the presence of constitutive membrane-
localized PKC. In this case, even with PKC activation there would be no visible translocation 
necessary for PKC to have effects.  
The stimulus necessary to trigger PKC translocation is particularly prone to variability, 
which is likely due to the artificially high concentrations of the stimulatory agents used (i.e. 
diacylglycerol and/or calcium). For example, one study investigating the role of various PKC 
isoforms in chemotherapy-mediated pain found that increases in intracellular calcium were 
sufficient to translocate several conventional and novel PKC isoforms (PKCβII, PKCδ and PKCε), 
but not others such as PKCα (He and Wang, 2015). However, in other cell systems, intracellular 
calcium increase is capable of translocating PKCα to the membrane (MAASCH et al., 2000).  
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Broadly, the role of PKCs in potentiating pain within dorsal root ganglia neurons and the 
spinal cord has been established (Aley et al., 2000). In the hyperalgesic priming model that is used 
to simulate the transition from acute to chronic pain, PKCε plays a vital role in facilitating 
sensitization (Aley et al., 2000, Hucho et al., 2005). In the CFA model of inflammation, thermal 
hyperalgesia is diminished with deletion of PKCβ, PKCγ and PKCδ but deletion of PKCα had no 
effect (Zhao et al., 2011). However, deletion of PKCα actually heightened mechanical allodynia 
in an injury model, underscoring the importance of the cellular environment in determining how 
PKCs function (Zhao et al., 2011). Administration of PKC activators and inhibitors in the 
periphery of rodents demonstrates that PKCs are capable of sensitizing afferents, enhancing 
currents through critical channels such as the heat-sensing TRPV1 and altering thermal and 
mechanical sensitivity (Khasar et al., 1999, Zhou et al., 2001, da Cunha et al., 2004, Velázquez et 
al., 2007). In the spinal cord, activation of PKCs with a broad activator decreases mechanical paw 
withdrawal thresholds (Sluka and Audette, 2006).  
PKCs influence nociceptive processing in a multitude of ways, with phosphorylation of 
targets being the primary effect. Commonly studied targets of PKC phosphorylation are membrane 
ion channels, such as the heat-sensing TRPV4, mechano-sensitive TRPA1, and voltage sensitive 
calcium channels (Stea et al., Snutch, 2005, Srinivasan et al., 2008, Rajasekhar et al., 2015). Both 
TRPV4 and TRPA1 contribute to inflammatory pain by becoming sensitized, by either lower firing 
thresholds or changing gating properties, and PKC involvement in these processes can have 
significant implications for nociceptive signaling (Mandadi et al., 2011a). Certain PKC isoforms, 
such as PKCβII and PKCε, have been shown to respond directly to TRPV1 activation (Mandadi 
et al., 2006, Mandadi et al., 2011d). Additionally, TRPV1 contains two phosphorylation sites that 
are targeted by PKCε (Numazaki et al., 2002). In most cases, however, non-selective inhibitors of 
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PKC are used to determine modulation of the membrane ion channels, and thus the role of specific 
isoforms and their targets are both unclear.  
While multiple PKC isoforms have been implicated in pain, our specific interest is in the 
PKCs involved in P2Y1 receptor signaling. Given the differences in PKC expression in dorsal root 
ganglion neurons, and the very restricted expression of P2Y1 in the IB4+ population, it is critical 
to further explore specific PKC isoforms that could potentiate P2Y1 receptor effects.  
1.3.3 Conventional PKC (cPKC) isoforms: expression and role in inflammatory pain 
Gq-coupled signaling, such by P2Y1 receptors, produces diacylglycerol (DAG) and causes release 
of calcium from IP3-activated internal stores (Figure 2), both of which can activate conventional 
PKC isoforms. Literature from cell lines and dorsal root ganglion neurons provides evidence that 
either DAG or calcium alone are sufficient to translocate conventional PKCs (cPKCs), and thus 
cPKCs can be considered the most plausible downstream effectors for Gq-coupled receptors such 
as P2Y1 and will be the focus of investigation in this dissertation. 
PKCα, PKCβI and PKCβII, and PKCγ isoforms make up the cPKC family (Figure 3). 
While PKCs are broadly expressed in many tissue types, there is evidence to suggest that PKCα 
and PKCβI/II are expressed in mouse dorsal root ganglion neurons but not PKCγ (He and Wang, 
2015, Usoskin et al., 2015). Most of the available literature on PKCα and the PKCβs is in platelets, 
though several studies involving cPKCs do exist that investigate their role in pain (Konopatskaya 
et al., 2009, Gilio et al., 2010). In rodent models for peripheral neuropathy-induced pain, 
intrathecal inhibition of PKCβII reduces mechanical and heat hypersensitivity (He and Wang, 
2015). In the CFA model of inflammation, thermal hyperalgesia was diminished with deletion of 
PKCβ but deletion of PKCα had no effect (Zhao et al., 2011). Within the same model, PKCβII 
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demonstrated increased membrane translocation that mirrored the length of the behavioral 
hyperalgesia caused by the inflammation (Igwe and Chronwall, 2001).  
While there are several studies investigating the behavioral effects of cPKCs in 
inflammatory models, the specific targets that cPKC acts on have not been sufficiently 
characterized in nociceptors. An exception is PKCβII, which translocates to the membrane 
following activation with the diacylglycerol (DAG) analog PMA and attenuates capsaicin-induced 
TRPV1 responses in rodent DRGs (Mandadi et al., 2011d). In embryonic nociceptive neurons from 
rats, PKCα is required for TRPV1 activation, though PKCα is not required in the same process 
postnatally (Olah et al., 2002). There is indirect evidence that the TRPM8 cold-sensing ion channel 
is modulated by cPKCs, as TRPM8 desensitization is dependent on extracellular calcium influx 
(Abe et al., Mandadi et al., 2011a). 
Outside of these studies, there is a dearth of information regarding cPKCs in inflammatory 
pain, especially as it relates to specific PKC isoforms and their targets. However, there is a clear 
role for cPKCs in inflammation and particularly a promising role within P2Y1 receptor signaling. 
The ability to further investigate cPKCs in nociceptive processes and develop techniques to 
identify targets of cPKCs would provide important information regarding the role of both P2Y1 
and cPKCs in pain. 
1.4 P2Y12 AND P2Y13 RECEPTORS: SIGNALING, EXPRESSION AND FUNCTION 
P2Y12 and P2Y13 Gi/o-coupled receptors are activated by the endogenous ligand adenosine 
diphosphate (ADP), which is produced by the enzymatic breakdown of ATP released in basal and 
inflammatory states (Vongtau et al., 2011a, Burnstock, 2012). P2Y12 and P2Y13 receptors 
 20 
(P2Y12/13) are expressed in small diameter neurons in the DRG, with P2Y13 expressed in a few 
larger diameter cells as well (Malin and Molliver, 2010). Additionally, P2Y12/13 receptors are 
found in peripheral immune cells, such as macrophages, and in central nervous system microglia 
(Table 1). Thus, similar to the other ADP-activated receptor, P2Y1, P2Y12/13 receptors are 
present in the various components involved in nociceptive signaling (i.e. immune cells, dorsal root 
ganglion neurons and within the spinal cord).  
The P2Y12/13 purinergic receptors are seven-transmembrane G-protein coupled receptors 
that are activated by the binding of the nucleotide adenosine diphosphate (ADP) to the N-terminal 
region of the receptor. The overall effect of Gi/o-coupled signaling is to inhibit the Gs-coupled 
signaling cascade member adenylyl cyclase (Figure 2), which is involved in pro-nociceptive 
signaling. Non-steroidal anti-inflammatory drugs (NSAIDs), for example, inhibit the production 
of prostaglandins that are released during inflammation, and prostaglandins activate certain Gs-
coupled receptors (Ricciotti and FitzGerald, 2011). Therefore, activation of Gi/o-coupled signaling 
is thought to provide a strong anti-nociceptive drive to the pro-nociceptive Gs-coupled system. 
Once P2Y12/13 receptors are activated, the Gαi/o and Gβγ subunits dissociate from the C-terminus 
(Figure 2) and the Gαi/o subunit then binds to adenylyl cyclases (ACs). The binding of the Gαi/o 
subunit to adenylyl cyclase alters its conformation such that cyclic adenosine monophosphate 
(cAMP) can no longer be produced. Protein kinase A (PKA) is the major downstream effector of 
Gs-coupled signaling and requires cAMP to become activated, so preventing cAMP synthesis 
effectively shuts down signaling through Gs-coupled receptors (Figure 2).  
Gi/o-coupled receptors are valuable as analgesics because they inhibit several critical pro-
inflammatory processes. First, Gi/o-coupled receptors inhibit the key Gs-coupled signaling 
component adenylyl cyclase as discussed above. Second, Gi/o-coupled receptors attenuate sensory 
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transmission by inhibiting voltage dependent calcium channels (VDCCs) through their Gβγ 
subunits (De Waard et al., 1997, Zamponi et al., 1997, Endoh et al., 2001, Malin and Molliver, 
2010). The inhibition of VDCCs prevents sensory transmission by attenuating the depolarization-
evoked influx of calcium cations, and thus the cell is less capable of being “excited.” Given that 
nociceptor sensitization is in part characterized by VDCC-mediated decrease in nociceptor firing 
thresholds, Gi/o-mediated blockade of VDCCs presents a substantial impediment to nociceptor 
sensitization (Herlitze et al., 1996, Ikeda, 1996, Arnot et al., 2000) 
Currently, the Gi/o-coupled opioid receptor agonists are considered the most effective 
analgesics for treating inflammatory pain, but they have severe dose-limiting side effects. The 
delicate balance between maximizing analgesia while minimizing side effects becomes even more 
difficult to maintain with prolonged opioid use for individuals with chronic pain. Therefore, it is 
imperative to discover and characterize receptors in a similar class, the Gi/o-coupled class, which 
can provide analgesia during treatment of inflammatory pain.  
1.4.1 The role of P2Y12 and P2Y13 receptors in peripheral inflammation  
Work from our laboratory has demonstrated the significant anti-nociceptive potential of P2Y12/13 
receptors in dorsal root ganglia neurons. Activation of P2Y12/13 receptors inhibits the 
depolarization evoked calcium transients in dissociated dorsal root ganglia neurons, indicating 
P2Y12/13 receptors are capable of attenuating sensory transmission (Malin and Molliver, 2010). 
This inhibition of calcium transients is likely mediated via inhibition of voltage dependent calcium 
channels. In the complete Freund’s adjuvant (CFA) inflammatory model, application of the 
selective P2Y13 agonist inosine diphosphate (IDP) at CFA day 3 temporarily reverses thermal 
hyperalgesia (Malin and Molliver, 2010). In the P2Y1KO mouse, administering the P2Y12/13 
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agonist ADP temporarily reverses thermal hypersensitivity produced by the inflammatory agent 
CFA (Malin and Molliver, 2010). 
 Outside of these key studies, P2Y12 and P2Y13 receptors have not been well characterized 
in inflammatory pain models. In humans, an irreversible P2Y12 antagonist by the name of 
‘clopidogrel’ (trade name Plavix) is used to inhibit blood clots in those with cardiac diseases (Savi 
et al., 2001). Interestingly, there have been numerous case studies linking clopidogrel use in 
patients to recurrent arthritic pain (Garg et al., 2000, Agrawal et al., 2013). Tests in a rat model of 
arthritis demonstrated that clopidogrel exacerbates the pro-inflammatory response in arthritic rats, 
which includes increased inflammation of the joint and leukocyte infiltration (Garcia et al., 2011). 
The effects seen were not associated with platelets, suggesting inhibition of endogenous activity 
of P2Y12 at other cell types is responsible for the arthritic pain seen in patients on clopidogrel. 
Given the evidence suggesting basal release of ATP, it is plausible that P2Y12 receptors are 
tonically active in nociceptors and providing anti-nociceptive tone. Relief of that endogenous tonic 
activation by clopidogrel would then be expected to promote nociceptive signaling and produce 
pain, as was shown by the case reports. While further studies are needed to directly link the arthritic 
pain caused by the P2Y12 antagonist clopidogrel to neuronal P2Y12 activity, the clinical studies 
provide compelling data implicating P2Y12 receptors as key anti-inflammatory mediators.  
There is limited data available on P2Y12 and P2Y13, both in animal models and clinical 
studies. However, the few studies that do exist provide persuasive evidence that P2Y12 and P2Y13 
receptors play an important role in dampening inflammatory pain. Investigating P2Y12 and P2Y13 
receptors further and elucidating their signaling cascades could provide additional support for the 
receptors’ importance as potential analgesics.  
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1.5 SUMMARY AND THESIS GOALS 
Purinergic receptors have long been implicated in the modulation of pain pathways. Our lab has 
previously demonstrated the importance of the purinergic P2Y1 Gq-coupled receptor in the 
development and maintenance of pain within the CFA model of inflammation (Malin and 
Molliver, 2010, Molliver et al., 2011, Jankowski et al., 2012). The P2Y1 receptor is also highly 
expressed in the IB4+ population of nociceptors, a population that is critical for the full 
presentation of mechanical and thermal hyperalgesia. The canonical downstream effector for all 
Gq-coupled receptors, such as the P2Y1 receptor, is protein kinase C (PKC), which once activated 
can translocate to the membrane and modulate membrane channels or proteins. While the 
importance of PKCs for Gq-coupled signaling has long been established, recent evidence suggests 
activation and function of individual PKC isoforms is not identical, with different PKC isoforms 
implicated based on the pain model used and the host system (Cesare et al., 1999, Zhao et al., 
2011, He and Wang, 2015). Given the crucial role of PKCs as effectors for P2Y1 receptor 
signaling, it is imperative to investigate the specific PKC isoforms involved in P2Y1-mediated 
effects within nociceptors.  
P2Y12 and P2Y13 receptors, like P2Y1, are activated by the nucleotide ADP. Unlike P2Y1 
receptors, however, the Gi/o-coupled P2Y12 and P2Y13 receptors have been shown to attenuate 
nociceptive activity in the CFA model of peripheral inflammation (Malin and Molliver, 2010). 
P2Y12 and P2Y13 receptors are also present in nociceptors, indicating that nociceptors expressing 
the P2Y1 receptor also likely express both P2Y12 and P2Y13. The fact that nociceptors contain 
all three ADP receptors is critical, as many studies that have investigated GPCR signaling cascades 
have used cell lines and not primary cells. These cell lines would not necessarily have the same 
expression of the ADP receptors as DRGs, and thus there is a skewed picture of the effects of 
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P2Y1/P2Y12/P2Y13 receptor activation with that literature. Additionally, there is simply a dearth 
of information regarding Gi/o-coupled purinergic receptors in the pain field regardless of the host 
system. Given that the current most effective analgesics for treating pain, opioids, also target Gi/o-
coupled receptors, uncovering the function of P2Y12 and P2Y13 receptors within nociceptors is a 
crucial step in understanding pain. 
The goal of this dissertation was to investigate the three ADP-activated purinergic 
receptors, P2Y1, P2Y12 and P2Y13 in nociception. I discovered that P2Y1 receptor signaling is 
mediated primarily through PKCα, with P2Y1-mediated mechanical hyperalgesia significantly 
attenuated following inhibition of PKCα. Additionally, PKCα is specifically expressed in 
cutaneous-projecting, but not visceral, nociceptors indicating a specific role for PKCα in cutaneous 
pain. I found that P2Y12 and P2Y13 receptors provide strong anti-nociceptive drive by inhibiting 
the Gs-coupled pathway and activation of P2Y12 and P2Y13 attenuates mechanical hyperalgesia 
through this pathway. Finally, all three purinergic receptors displayed activity at baseline, 
supporting the novel idea that there is tonic nucleotide release that helps set basal nociceptive tone. 
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2.0  CHARACTERIZATION OF CONVENTIONAL PKC ISOFORMS IN MOUSE 
SENSORY NEURONS AND THEIR ROLE IN P2Y1-MEDIATED NOCICEPTION 
2.1 BACKGROUND 
Numerous G protein-coupled receptors (GPCRs) coupled to Gq/11 participate in the sensitization 
of nociceptors by inflammatory mediators. Conventional PKC isoforms (cPKC), which require 
both Ca2+ and diacylglycerol (DAG) for activation, appear likely effectors for Gq/11 signaling, 
because both stimuli are produced by Gq/11-induced activation of phospholipase C. Here, we 
examined the distribution of cPKC isoforms PKCα, PKCβI and PKCβII in sensory neurons of the 
mouse dorsal root ganglion (DRG) and examined their activation by the Gq/11-coupled nucleotide 
receptor P2Y1, which is required for inflammatory sensitization of cutaneous polymodal 
nociceptors.  
The distribution of immunohistochemical staining for PKCα in lumbar DRG was 
consistent with abundant expression in small diameter cutaneous but not visceral (bladder and 
colon) afferents, but staining was not colocalized with markers for unmyelinated low threshold 
mechanoreceptors. Quantitative single cell PCR confirmed that PKCα is broadly expressed in 
afferents identified by expression of the GPCR MrgprD and binding of the lectin IB4. Antisera 
selective for phospho-serine-containing substrate proteins for cPKC (p-SercPKC) labeled DRG 
neurons with a distribution nearly identical to that of PKCα, suggesting that PKCα is tonically 
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active in naive DRG. Separation and quantification of p-SercPKC labeled proteins by Western and 
slot blot following inflammatory injury demonstrated a consistent phosphoprotein profile and 
increased cPKC activity in response to inflammation. Hindpaw injection of the P2Y1 agonist 
2MeSADP produced mechanical hyperalgesia that was attenuated by the preferential inhibitor of 
PKCα/PKCβI, GF109203X. Based on these results, we propose that PKCα, and to a lesser extent 
PKCβII, contribute selectively to cutaneous nociceptive signaling.  
2.2 INTRODUCTION 
Inflammation of peripheral tissues causes persistent sensitization of peripheral sensory neurons of 
the dorsal root ganglia (DRG) that detect noxious stimuli (nociceptors) through a cascade of 
proalgesic substances released by immune cells and the inflamed tissue (Eastgate et al., 1988, 
Dickson et al., 1993, Hamilton et al., 2000, Verri Jr et al., 2006, Cunha et al., 2007, Chen et al., 
2010, Wei et al., 2012). Numerous components of this ‘inflammatory soup’ act at G-protein coupled 
receptors (GPCRs) expressed by nociceptors (Sun and Ye, 2012). Protein kinase C (PKC) is a major 
downstream effector for Gq/11-coupled receptors, and several PKC isoforms have been implicated 
in the modulation of ion channel function in sensory neurons in response to peripheral inflammation 
(Cesare et al., 1999, Khasar et al., 1999, Bhave et al., 2003, Mandadi et al., 2011d).  
The PKC family is broken into three groups, which are distinguished by the presence or 
absence of a C2-calcium binding domain and responsiveness to diacylglycerol: conventional 
members (cPKC) are activated by calcium and diacylglycerol (DAG), novel members (nPKC) 
require only DAG, and atypical (aPKC) are insensitive to DAG and phorbol esters but are activated 
by phosphatidylserine (Nishizuka, 1992, Mosior and Newton, 1995, Mackay and Twelves, 2007). 
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Because Gq/11-coupled receptors activate phospholipase C β isoforms to produce diacylglycerol 
and increase intracellular calcium, cPKC isoforms are strong candidates as effectors for Gq-
coupled receptor mediated signaling.  
Work from our lab and colleagues previously reported that the purinergic Gq/11-coupled 
receptor P2Y1 is required for normal thermal sensitivity in a subset of unmyelinated sensory 
neurons representing roughly half of all unmyelinated DRG neurons that are commonly identified 
by binding of the plant lectin IB4 (Molliver et al., 2011, Jankowski et al., 2012). This population 
is often referred to as “nonpeptidergic” due to the paucity of the proinflammatory neuropeptides 
calcitonin gene-related peptide (CGRP) and substance P, particularly in the mouse. IB4+ DRG 
neurons provide the majority of epidermal nociceptive innervation and appear particularly 
important for noxious mechanosensation (Plenderleith and Snow, 1993, Bennett et al., 1996, Perry 
and Lawson, 1998, Joseph and Levine, 2010), although most are also capable of transducing 
noxious heat and/or cold stimuli (Stucky and Lewin, 1999, Molliver et al., 2011). Ablation of this 
neuronal population results in greatly diminished mechanical hypersensitivity in response to 
inflammatory injury (Vulchanova et al., 2001, Cavanaugh et al., 2009).  
Restricted expression of individual PKC isozymes could have significant ramifications for 
the regulation of nociceptor response properties by GPCRs. Three cPKC family members are 
expressed in mouse DRG as determined by Western blot and RT-PCR: PKCα, PKCβI and PKCβII 
(Khasar et al., 1999). Microarray data (unpublished data kindly shared by Dr. Silvia Arber, 
Friedrich Miescher Institute for Biomedical Research) suggested that of the cPKC family 
members, only PKCα is preferentially expressed within the IB4+ population of DRG neurons. Our 
own preliminary data indicated that PKCβII is also expressed in some IB4+ neurons, whereas 
PKCβI is primarily found in large diameter neurons. Given the possibility that P2Y1, PKCα and 
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PKCβII are broadly co-expressed in nociceptive sensory neurons, we investigated the distribution 
of these isozymes in DRG neurons and their functional regulation in response to peripheral 
inflammation. In addition, we used retrograde tracing to demonstrate that PKCα and PKCβII are 
broadly expressed in cutaneous afferents but largely excluded from visceral (bladder and colon) 
afferents. 
2.3 MATERIALS AND METHODS 
Animals 
Adult male C57BL6 mice (2-4 months old) were used for all experiments and housed in group 
cages in a temperature-controlled environment. Tissue from VGLUT3-eGFP mice (Seal et al., 
2009) was graciously provided by Dr. Rebecca Seal (University of Pittsburgh, Pittsburgh PA). 
Mice were given ad libitum access to food and water and maintained in a 12-hour light-dark cycle. 
Experiments and procedures were conducted with strict adherence to the Institutional Animal Care 
and Use Committee of the University of Pittsburgh guidelines and the NIH Guide for the Care and 
Use of Laboratory Animals.  
 
Primary neuron dissociation 
DRG neurons were dissociated using a modification of a previously published protocol (Malin et 
al., 2007). Briefly, following overdose with avertin anesthetic, mice were transcardially perfused 
with ice-cold Hank’s balanced salt solution (HBSS, GIBCO). All DRGs were promptly dissected 
and placed into a papain enzyme solution (60U, Worthington BioChem) for 10 minutes at 37C. 
After removal of the papain solution, the DRG neurons were incubated in a dispase/collagenase 
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enzyme solution for 20 minutes at 37C. Fire-polished Pasteur pipettes were used to gently 
dissociate the cells, taking care to minimize the number of titurations. The dissociated neurons 
were plated onto poly-D lysine/laminin-coated Millipore EZ chamber slides and plated in complete 
media, consisting of F12 (GIBCO), 10% fetal bovine serum (Invitrogen) and 1% 
penicillin/streptomycin (GIBCO), at 37C. After 90 minutes, additional complete media was 
applied, and cells were analyzed within 16-24 hours after plating. In several experiments to 
demonstrate PKCα translocation at shorter incubation times, neurons were plated with F12 
complete media for 1.5 hours before use. 
 
Immunohistochemistry  
Animals were given an overdose of avertin anesthetic and transcardially perfused with ice-cold 
PBS followed by 4% paraformaldehyde. All DRG neurons and the lumbar spinal cord were 
removed and placed into 20% sucrose overnight at 4C for cryoprotection. Individual DRG neurons 
and lumbar spinal cord were placed into OCT embedding medium and sectioned using a cryostat 
(DRG at 12 µm thickness and spinal cord at 20 µm) and collected on Superfrost slides (Fisher). 
Sections were blocked for 30 minutes with a 1X PBS solution containing 2.0% normal horse serum 
and 0.2% Triton X-100. The sections were then incubated overnight in a humid chamber with 
primary antibody diluted in the same blocking solution as above. Following three washes with 1X 
PBS (5 minutes each), the sections were incubated in secondary antibody diluted in blocking 
solution for 60 minutes. The sections were washed again with 1X PBS (3X, 5 minutes each) and 
coversliped using Dako, an anti-bleaching mounting medium.  
The primary antibodies used were as follows: polyclonal rabbit anti-PKCα (1:2000, Santa 
Cruz biotechnology, Cat. No. SC-208), polyclonal rabbit anti-phospho-(ser)-PKC (p-SercPKC, 
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1:2000, Cell Signaling, Cat. No. 2261), goat anti-GFRα3 (1:250, R&D Systems, Cat. No. 
AF2645), polyclonal rabbit anti-PKCβII (1:1000, Santa Cruz biotechnology, Cat. No. SC-210), 
goat anti-p-PKCα (1:1000 Santa Cruz biotechnology, Cat. No. SC-12356), rabbit anti-tyrosine 
hydroxylase (TH) (1:500, Chemicon, Cat. No. AB152) and IB4 conjugated to Cy2 (IB4 488, 1:200, 
ThermoFisher Scientific, Cat. No. I21411 ). All secondary antibodies were obtained from Jackson 
ImmunoResearch Laboratories and were as follows: Cy3-conjugated donkey anti-rabbit, Cy2-
conjugated donkey anti-goat and Cy5-conjugated donkey anti-goat.   
The proportion of neurons immunoreactive for a given marker was quantified using the 
systematic random sampling approach: cell bodies with clearly defined nuclei that were clearly 
stained above background were counted in five evenly spaced sections from a single ganglion 
(every nth section, where n=total number of sections/5) as described previously (Pakkenberg and 
Gundersen, 1988, Vongtau et al., 2011a). Counts from one ganglion/one mouse were considered 
an n of 1 for statistical analysis and used to generate means ± SEM for the number of mice stated 
in the text. The number of neurons positive for either PKCα or PKCβII that were also IB4 or 
GFRα3 positive were calculated as a percentage and expressed as mean % positive ± SEM. 
 
Single cell polymerase chain reaction (ssPCR) 
Cell dissociation 
DRGs containing labeled cells were removed and dissociated as described previously (Malin et 
al., 2007). Briefly, DRGs were treated with Papain (30 U) followed by Collagenase Type II (10 
U) /Dispase type II (7 U), centrifuged (1 minute at 100g), triturated in MEM, and plated onto 
laminin-coated coverslips in 30mm diameter dishes. Cells were cultured in an incubator at 37ᵒC 
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for 45 minutes. Dishes were removed and flooded with collection buffer (140mM NaCl, 10mM 
Glucose, 10mM HEPES, 5mM KCl, 2mM CaCl2, 1mM MgCl2). 
 
 
Single Cell Preamplification and qPCR 
The RNA collected from each cell was nonselectively reverse transcribed and amplified using T7 
linear amplification (Epicentre, MessageBOOSTER kit for cell lysate). The lysate was then 
cleaned (Zymo Research, RNA Cleaner & Concentrator-5 columns) and evaluated using qPCR 
with optimized primers as described previously (Jankowski et al., 2009) and SsoAdvanced SYBR 
Green Master Mix (BIO-RAD). Quantification cycle (Cq) values were determined via regression. 
 
 
 
 
Table 2: Primer efficiencies for GAPDH, PKCα and MRGD 
 
Primer creation and validation 
Unique forward and reverse primer sequences were chosen for each gene within 500 bases of the 
3’ end (Table 2). Stock solutions of cDNA were generated by extracting RNA from the whole 
DRG as described in Jankowski et al., 2009 and 10 or 160pg aliquots of the RNA were 
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preamplified as described for single cells to create stock solutions for primer calibration. Serial 
dilutions of these aliquots were used to calculate primer efficiencies over the range of RNA 
concentrations observed in single cells (Figure 4). Levels of specific genes are expressed relative 
to GAPDH and corrected for relative primer efficiencies (Pfaffl, 2004). 
Exclusion criteria for cell mRNA expression 
In order to determine what constitutes a cell that expresses the gene of interest versus not, a limit 
of detection (LoD) was established based on established literature (Nutz et al., 2011). The LoD 
was defined as the point at which PCR replicates give measurable responses 95% of the time.  
Figure 4: Primer efficiency curves for GAPDH, PKCα and MRGD 
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Retrograde Labeling 
Bladder afferents  
Alexa Fluor-conjugated cholera toxin-β (CTβ) (Life Technologies) dissolved in sterile saline was 
injected into surgically exposed bladder wall (approximately 3µL/site, 2-4 sites total). The mice 
were sacrificed 4 days post-injection and transcardially perfused with ice-cold 4% 
paraformaldehyde. L6-S1 DRG were dissected and post-fixed for 1 hour in 4% paraformaldehyde 
at 4C. The tissue was processed for immunohistochemistry as described above (Christianson et al., 
2007).  
Colon afferents 
Fast blue (FB, 1% in sterile saline, EMS-Chemie, Gross-Umstadt, Germany) was injected into 
surgically exposed distal colon (approximately 3μl/site, 3-5 sites total). The mice were sacrificed 
3-4 weeks following injection and transcardially perfused with ice cold Lana’s fixative. The DRG 
was processed for immunohistochemistry as described above (Christianson et al., 2007). Tissue 
sections were generously provided by Dr. Jun-Ho La at the University of Pittsburgh.  
Hindpaw afferents 
DiI (1,1'-Dioctadecyl-3,3,3',3'-Tetramethylindocarbocyanine Perchlorate, Molecular Probes) 
dissolved in DMSO (170μg/ml) and further diluted in 1:10 sterile saline for injection (final 
concentration 17μg/ml) was injected into glabrous hindpaw (approximately 5µL/site, 2-4 sites 
total). The mice were sacrificed 14 days following injection and transcardially perfused with ice-
cold 4% paraformaldehyde. L2-L5 DRG were dissected and post-fixed for 1 hour at 4C. The tissue 
was processed for immunohistochemistry as described above, however the blocking buffer was 
made with digitonin (Cayman Chemicals) rather than Triton-100 to preserve DiI staining.  For 
each target tissue, the percentage of retrogradely labeled neuronal cell bodies that displayed 
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immunoreactivity for PKCα or PKCβII was determined for each animal (n=4 animals/ target 
tissue). 
Translocation assay and analysis 
Dissociated DRG neurons were prepared as described and incubated overnight. Complete media 
was replaced with F12 media (GIBCO) for 30 minutes at 37C. To activate PKC a diacylglycerol 
analog, phorbol-12-myristate-13-acetate (PMA, 1µm in F12, LC Labs), or P2Y1 agonist 2-
Methylthioadenosine diphosphate (2MeSADP, 100µm in F12, Tocris), was applied for 5 minutes 
at 37C. For control conditions, F12 media was placed onto the cells for 5 minutes. Neurons were 
briefly rinsed with F12 and fixed in ice-cold 4% paraformaldehyde for 10 minutes. The cells were 
then washed with 1X PBS 3x for 5 minutes each and then incubated at room temperature with 
blocking buffer (1X PBS solution containing 2.0% normal horse serum and 0.2% Triton X-100) 
for 30 minutes. The primary antibodies were diluted in this same blocking buffer and applied 
overnight at room temperature. Following a second series of 1X PBS washes (3x/5min each), the 
secondary antibody diluted in blocking buffer was applied for 30 minutes and then washed for a 
final time with 1X PBS as before. The slide was then dipped briefly into distilled water and 
coversliped using anti-fade mounting medium (Dako). Images were obtained using a Nikon A1+ 
confocal microscope at 60× magnification.  Maximum intensity projection images were obtained 
from 5-9 optical sections per coverslip and images were analyzed using ImageJ and processed for 
final presentation using Adobe Photoshop. The experimenter was blinded to the treatment 
conditions.  The percentage of cells displaying clear translocation, defined as bright staining along 
the cell membrane and a relative absence in the cytoplasm, was quantified. SigmaPlot (Systat 
Software Inc.) was used to produce the final graphs. 
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Slot and Western Blots 
Slot-Blot Assay  
DRGs were isolated and cultured overnight as described previously (Malin et al., 2007). Complete 
media (MEM 10%FBS + Pen/strep) was removed and the cultured DRG neurons were incubated 
with vehicle, phorbol 12-myristate 13-acetate (PMA, 1μM) alone, GF109203X (PKCα inhibitor, 
1μM), CGP 53353 (PKCβII inhibitor, 4.1μM), or PMA + GF109203X and/or CGP53353. 
GF109203X and CGP53353 were pre-incubated for 10 min, after which PMA was added to the 
DRGs for 30 min. The drug solution was removed and the cultured DRGs washed twice with PBS 
and reaction stopped by adding 500μL of 10% ice-cold TCA. Samples were incubated on ice for 
30 min and then, using a cell culture scraper, all cells were collected and placed into Eppendorf 
tubes. The collected cells were centrifuged for 10 min at 4C and the supernatant was carefully 
removed and discarded. The pellet was re-suspended in 15-25μL of DiGE buffer. 
   PVDF membrane was activated and equilibrated in TBS buffer, then washed with 200 μl TBS 
per well. All sample solutions were made in 200 μl TBS. Samples were applied to the membrane 
using a Bio-Rad Bio-Dot SF vacuum manifold, and then wells were washed twice with at least 
200 μl of TBS. The membrane was removed from the apparatus and blocked with 2.5% BSA 
solution made in TBS for 1 hour at room temperature, washed twice with TBS-T buffer for 10 
minutes with gentle agitation and incubated in primary antibody solution overnight at 4°C. The 
membrane was washed in TBS-T three times for 10 minutes with gentle agitation and incubated 
in secondary antibodies conjugated to Cy2, Cy3, or Cy5 (Jackson ImmunoResearch) for 2 hours 
at room temperature, then washed three times again. Fluorescence images were acquired using a 
FluoChem Q blot imager (Cell Bioscience, Santa Clara CA) or a Typhoon FLA 9500 scanner (GE 
Healthcare, Piscataway NJ) and analyzed by AlphaView or ImageQuant TL Software. Bands were 
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quantified by densitometry and normalized to GAPDH or total protein visualized after background 
subtraction. 
Western Blot  
DRGs were collected onto dry ice and homogenized in a 0.5ml tube with a plastic pestle in lysis 
buffer (7 M Urea, 2 M Thiourea, 4% CHAPS, 30 mM Tris-HCl at pH 8.5) containing protease and 
phosphatase inhibitors. The lysate solution was incubated on ice for 20 min and centrifuged for 5 
min at 10,000g. Supernatant was placed in a fresh tube and stored at -20°C. Protein samples were 
quantified using GE Healthcare 2D Quant kit (GE Healthcare, Piscataway NJ).  
   Frozen lysate samples were thawed on ice, premixed with 5X Laemmli loading buffer and 20 
μg of total protein was loaded per lane for gel electrophoresis onto 12% SDS polyacrylamide gels 
using Mini Gel Tanks (Life Technologies, Grand Island NY) and transferred to PVDF membrane 
with Mini Trans-Blot Cell (Bio-Rad, Hercules CA) and exposed to antibodies for fluorescence 
visualization and quantification as above using GAPDH reacted simultaneously on the same blot 
as a reference standard.  
 
Mechanical threshold testing 
Behavioral data were collected in the Rodent Behavior Analysis Core at the University of 
Pittsburgh Schools of Health Sciences.  Mice were acclimated in individual plexiglass chambers 
for 60 min/day for 3 days prior to testing. Von Frey mechanical stimulation (vF #3.61, equivalent 
to 0.4g force) was applied to the plantar hindpaw and paw withdrawal frequencies were determined 
based on the number of withdrawals out of 10 trials per mouse, with 10 withdrawals out of 10 
trials corresponding to 100% withdrawal frequency (Schwartz et al., 2008). A baseline 
measurement was made prior to injection of the drug and then responses were recorded at 30, 60, 
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120 min and 24 hr post-injection. Drugs were diluted in saline immediately before injection, with 
the experimenter being blinded to the conditions. The P2Y1 receptor agonist, 2MeSADP (Tocris, 
10nmols/10uL), and inhibitors of PKCα and PKCβII, GF109203X and CGP 53353 (Tocris, 84nM 
and 4.1uM respectively), were injected into the plantar hindpaw. Statistical analysis was done 
using a two-way repeated measures analysis of variance (ANOVA) followed by Bonferroni post 
hoc test. All data were analyzed and processed using SigmaPlot (version 12.0, Systat Software 
Inc.). 
2.4 RESULTS 
Distribution of conventional PKC isozymes in mouse DRG 
The distribution of PKCα and PKCβII was analyzed in L2-5 lumbar DRG neurons by 
immunohistochemistry, using cell type-specific markers to delineate subsets of sensory neurons 
(Figure 5A-C). Small diameter sensory neurons, which are likely to be unmyelinated, can be 
grossly divided into two subsets of roughly equal size, the “peptidergic” population, which show 
high levels of calcitonin gene-related peptide (CGRP) and express the nerve growth factor receptor 
TrkA, and the “nonpeptidergic“ population, which extensively express the G protein-coupled 
receptor MrgprD and bind the plant lectin IB4. In mouse (more so than in rat), only a small 
percentage of neurons positive for IB4 express the heat- and acid-gated ion channel TRPV1 
(Woodbury et al., 2004), whereas virtually all TRPV1-expressing neurons fall within the 
peptidergic population. In this study, we used the artemin receptor GFRα3 as a surrogate marker 
for TRPV1 because the TRPV1 antibody is generated in rabbit, making double-labeling with other 
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rabbit antibodies difficult. More than 90% of GFRα3-positive neurons express TRPV1 (Orozco et 
al., 2001, Elitt et al., 2006, Malin et al., 2006). 
DRG sections stained with antibodies to PKCα showed bright fluorescence and diffuse 
cytoplasmic localization in a subset of primarily small-diameter neuronal cell bodies. Many 
neurons showed increased intensity of staining associated with the plasma membrane. Occasional 
neurons were observed with faint staining slightly above background, many of them large in 
diameter, but these cells were clearly distinguishable from the intensely stained majority and were 
considered negative for the purpose of this analysis. Neuronal cell bodies with intense PKCα 
staining represented 43 ± 7.5% of all DRG neurons (Figure 5B, 233/543 neurons, n=4 animals) 
and PKCβII labeling was present in 26 ± 2.2% of neurons (Figure 5B, 100/388 neurons, n=4 
animals). 86.0 ± 4.0% of all IB4-positive neurons were also positive for PKCα (Figure 5A and C, 
434/505 IB4+ neurons, n=4 animals). GFRα3 staining overlapped with only 23.7 ± 8.2% of PKCα-
positive neurons (Figure 5A and C, 65/335 cells, n=4 mice). As expected, overlap between 
GFRα3 and IB4 staining was limited: only 7% of IB4-labeled cells were also positive for GFRα3 
(28/402 cells, n=3 mice).  
The distribution of PKCa staining was identical when an antibody generated against 
phospho-PKCa (p-PKCα) was used. This residue is a constitutive auto-phosphorylation site 
considered to be required for functional enzyme. Use of two different antibodies generated against 
different epitopes of the same protein improves confidence in the selectivity of the staining; 
identification of a selective PKCα antibody generated in goat provided a useful tool for double-
labeling studies. 
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Figure 5: PKCα and PKCβII are differentially expressed in peptidergic and nonpeptidergic 
populations. Staining for PKCα and PKCβII (A) in sections of L2-L5 DRG neurons and dorsal 
horn triple-labeled with the nonpeptidergic population marker IB4 and peptidergic population 
marker GFRα3. PKCα positive DRG neurons account for slightly less than half of total DRG 
counted, whereas PKCβII positive DRG neurons account for around 1/5th of total DRG neurons. 
The vast majority of PKCα neurons bind IB4, with relatively few PKCα neurons showing GFRα3 
co-expression. PKCα staining is present in both lamina I and II in the dorsal horn, encompassing 
IB4+ and GFRα3 staining. PKCα staining is present in intrinsic dorsal horn neurons as well. The 
majority of PKCβII expressing cells do not express either IB4 or GFRα3. PKCβII staining in the 
dorsal horn encompasses both lamina I and lamina II. Asterisks (*) indicate co-expression with 
IB4+ neurons, arrows indicate intrinsic spinal cord cells and arrowheads show co-expression with 
GFRα3. 
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To visualize the distribution of PKCα-containing central projections, lumbar spinal cord 
sections were stained for PKCα and the nociceptor subpopulation markers GFRα3 and IB4. IB4-
binding neurons project preferentially to the inner part of lamina II in the spinal dorsal horn, while 
the GFRα3-positive subpopulation terminates in lamina I and outer II (Stucky and Lewin, 1999). 
PKCα staining (Figure 5A) included intrinsic spinal dorsal horn neurons as well as primary 
afferent central projections, and as a result encompassed the entirety of laminae I and II. 
Expression in dorsal horn neurons is consistent with the results of a previous study examining 
PKCα function in the CNS (Kopach et al., 2013).  
PKCβII staining was present in equivalent proportions of IB4-positive and GFRα3-positive 
neurons (Figure 5A and C; 13.3 ± 4.3%, 41/309 IB4+ neurons and 14.6 ± 8.4% 37/254 GFRα3 
neurons, n=4 animals), but also labeled many large diameter neurons. In lumbar spinal cord, 
PKCβII staining was present in primary afferent central projections in laminae I and II, however 
no staining was evident in intrinsic spinal cord neurons (Figure 5A). 
Most IB4-positive and GFRα3-positive DRG neurons are unmyelinated (C-fibers) and 
therefore likely to be nociceptors. However, not all C-fibers fit neatly into the peptidergic/TRPV1 
and nonpeptidergic/IB4 designation, and not all C-fibers are nociceptors. Several markers have 
been reported to identify innocuous (non-nociceptive) mechanically-sensitive C-fiber DRG 
neurons, including tyrosine hydroxylase (TH) and the type 3 vesicular glutamate transporter 
(VGLUT3). Neurons expressing TH and VGLUT3 include a population of C-fibers that respond 
to low threshold innocuous mechanical stimuli (CLTMR fibers), but do not encode noxious stimuli 
(Brumovsky et al., 2006, Takashima et al., 2007, Seal et al., 2009). There is approximately 95% 
co-expression between TH-labeled and VGLUT3 expressing DRG neurons (data not shown). We 
used these markers to examine the extent to which PKCα and PKCβII are expressed in 
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unmyelinated DRG neurons that are unlikely to be nociceptors. VGLUT3-eGFP reporter mice 
were analyzed because the PKCβII and TH antibodies were made against a rabbit host, and thus 
co-staining was not possible. Staining for both PKCα and PKCβII did overlap with TH-positive 
staining (Figure 6; 0/128 PKCα cells were TH-positive cell, 0/149 PKCβII cells were TH-positive 
cells), and was not evident in VGLUT3-eGFP+ neurons. It is therefore likely that PKCα and 
PKCβII are not expressed by non-nociceptor subtypes.  
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Figure 6: Staining for PKCα and PKCβII is excluded from C-fiber low threshold 
mechanoreceptors (CLTMRs). Staining for PKCα and PKCβII in sections of L2-L5 DRG 
neurons double-labeled with markers for the C-LTMR population: tyrosine hydroxylase (TH) and 
VGLUT3-eGFP transgenic mice. Analysis of L2-L5 DRG sections from WT mice stained with 
TH and VLGUT3-eGFP reporter mice indicates no overlap of PKCα and PKCβII with the C-
LTMR population. Plus signs (+), these are too large, should use arrows here, denote TH/VGLUT-
3 neurons and asterisks (*) PKCα or PKCβII. Scale bars indicate 20μm 
 
Distribution of PKCα mRNA in individual DRG neurons  
Single cell real-time PCR was performed to examine the expression of PKCα mRNA and 
coexpression with MrgprD, a marker of unmyelinated epidermal afferents that is highly 
colocalized with IB4 binding (Zylka et al., 2005). DRG were acutely dissociated and individual 
neurons collected for analysis of PKCα and MrgprD expression, using GAPDH as a reference 
standard. Of 60 neurons analyzed, 61.6% expressed detectable levels of PKCα mRNA (37/60 
cells) and 30% expressed MrgprD mRNA (18/60). 45.9% of PKCα expressing cells also expressed 
MrgprD (17/37 cells) whereas 94.4% of MrgprD positive neurons also expressed PKCα (17/18 
cells). Furthermore, the expression level (∆Ct value) of PKCα positively correlated with that of 
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MrgprD: the mean expression level of PKCα was 5.9-fold higher in MrgprD-expressing neurons 
compared to PKCα-expressing neurons that lacked MrgprD (Figure 7). 
 
 
Figure 7: PKCα mRNA expression in single dorsal root ganglia neurons correlates with the 
MrgprD population. Real-time PCR analysis of single cells from cultured L2-L5 dorsal root 
ganglia neurons. (A) The extent of PKCα and MrgprD mRNA expression is correlated, with high 
PKCα mRNA expressing cells also demonstrating high MrgprD mRNA expression (17 cells, 
R=0.58). Each diamond on the graph represents one neuron. (B) In cells that express both PKCα 
and MrgprD mRNA, the average ∆CT value of PKCα is 1.76 (17 cells) and MrgprD is 3.94 (17 
cells). In cells expressing PKCα, but not MrgprD, the average ∆CT value of PKCα mRNA is 4.25 
(20 cells). Cells that express MrgprD mRNA, but not PKCα, have an average MrgprD ∆CT value 
of 6.16 (1 cell). Single cells collected from n=3 independent cultures. 
 
Differential distribution of cPKCα and PKCβII in cutaneous versus visceral afferents 
As IB4-binding neurons provide the majority of epidermal innervation and we observed extensive 
colocalization of IB4 and PKCα staining, we used retrograde tracing from skin, colon and bladder 
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to determine the extent to which PKCα is preferentially expressed in cutaneous versus visceral 
afferents (Molliver et al., 1995, Bennett et al., 1996, Molliver et al., 1997, Stucky and Lewin, 1999, 
Zylka et al., 2005). Immunohistochemical examination of skin sections from the glabrous footpad 
revealed intense labeling for PKCα in afferents innervating the epidermis, demonstrating 
substantial innervation of the skin by PKCα-containing afferents (Figure 8C). This finding also 
indicates that PKCα is present at the site of sensory transduction in the peripheral terminals of 
unmyelinated afferents. We were unable to resolve any staining for PKCβII in cutaneous afferents, 
which may be due to the relatively low expression of PKCβII in cutaneous afferents but could also 
be due to technical limitations. Sections from bladder and colon revealed no afferent axon staining 
for either PKCα or PKCβII (data not shown).  
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Figure 8: PKCα and PKCβII are broadly expressed in cutaneous but not visceral afferents. 
Retrogradely labeled dorsal root ganglia neurons from footpad, colon and bladder stained with 
PKCα and PKCβII. PKCα was expressed in 57.3% of DiI back-labeled DRGs, indicating the 
majority of PKCα positive neurons are in cutaneous innervating DRGs (114/199 back-labeled 
neurons). PKCβII was expressed in 14.62 ± 8.3% of back-labeled footpad DRGs (19/130 back-
labeled neurons). None of the Fast Blue back-labeled colon DRGs neurons expressed PKCα (0/49 
back-labeled cells). 4 ± 1.08% of the back- labeled colon DRGs neurons expressed PKCβII (3/74 
back-labeled cells). Less than 4 ± 2.0% of back-labeled bladder neurons expressed PKCα (3/87 
back-labeled neurons). 0.68 ± 1.8% of back-labeled bladder neurons expressed PKCβII (1/147 
back-labeled neurons). Asterisks (*) indicate back-labeled cells expressing cPKC. n=3-4 
animals/target tissue. Scale bars indicate 10μm. 
 
To confirm whether visceral or somatic targets are innervated by PKCα and PKCβII 
expressing afferents, colon and bladder were injected with retrograde tracers in adult mice and the 
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corresponding DRGs were dissected and stained for PKCα and PKCβII. PKCα was widely present 
in cutaneous afferent cell bodies (Figure 8A and B, 57.3 ± 4.8%, 114/199 total back-labeled 
neurons), with very limited expression in DRG neurons innervating the bladder (Figure 8A and 
B, 3.4 ± 2.0%, 3/87 total back-labeled neurons) or colon (Figure 8A and B, 0/49 total back-labeled 
cells). Moreover, PKCα staining seen in the bladder afferents was substantially less intense 
compared to PKCα-positive cutaneous afferents or the positive staining shown in Figure 5.  
The distribution of PKCβII staining in cutaneous afferents was more limited than that of 
PKCα (Figure 8A and B, 14.7 ± 8.3%, 19/130 total back-labeled neurons), but PKCβII was 
similarly excluded from most visceral afferents (Figure 8A and B; bladder: 0.7 ± 1.8%, 1/147 
back-labeled neurons and colon: 4.1 ± 1.8%, 3/74 total back-labeled neurons). These results 
indicate that PKCα, and to a lesser extent PKCβII, are widely expressed in cutaneous afferents, 
but almost entirely excluded from bladder and colon afferents.  
 
PKCα and PKCβII translocation following activation 
The P2Y1 Gq-coupled receptor displays preferential expression in the IB4+ population and its 
canonical signaling pathway leads to DAG production and calcium release, both of which are 
necessary for conventional PKC isoform (i.e. PKCα and PKCβII) activation. Functional activation 
of PKC is generally thought to require translocation of the kinase to the membrane, where it then 
phosphorylates locally available substrate proteins. Therefore, we tested the ability of PKCα and 
PKCβII to translocate to the membrane following application of the DAG analog, phorbol 12-
myristate 13-acetate (PMA), and the P2Y1 receptor agonist, 2-methylthio adenosine diphosphate 
(2MeSADP). All data shown represent a 5 minute application time of each drug as previous studies 
have demonstrated translocation of PKC within 5 minutes of PMA application (Mandadi et al., 
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2011d). Time points between 30 seconds and 60 minutes were tested and displayed similar 
characteristics to the 5-minute time point (data not shown).  
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Figure 9: PKCβII translocates following PMA and P2Y1 receptor stimulation, whereas 
PKCα does not. DRG neurons cultured overnight were stimulated with 2MeSADP (100μM, 5 
min) or PMA (1μM, 5min) and then fixed with 4% paraformaldehyde. Neurons were stained with 
PKCα or PKCβII antibodies and the number of cells showing membrane staining were counted. 
Cells were considered having PKC translocation if there was a clear ring visible around the 
membrane. A. PKCβII staining was localized to the membrane in 46.41 ± 19.77% of cells 
stimulated by PMA (19/41) and 4.43 ± 3.40% by 2MeSADP (3/77). B. PKCα did not translocate 
in response to 2MeSADP or PMA (117 neurons were analyzed). Arrows indicate neurons with 
translocated PKC. Images were taken at 60X on a confocal microscope using the z-stack function. 
The maximum intensity projection image was used for cell counting. n=3-4 independent 
cultures/condition.  
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Surprisingly, in dissociated DRG neurons cultured for 24 hours, we did not observe any 
increase in membrane-associated PKCα staining in response to PMA (Figure 9B, 0/62 PKCα-
positive cells, n=4 animals). Application of 2MeSADP also had no effect on PKCα localization 
(Figure 9B, 0/55 PKCα-positive cells, n=4 animals). In contrast, PKCβII displayed robust 
translocation following PMA stimulation in 46.41 ± 19.77% of neurons (Figure 9A, 19/41 cells, 
n=3 animals). Application of 2MeSADP had a much smaller effect, with approximately 4.43± 
3.40% of neurons displaying PKCβII translocation (Figure 9A, 3/77 cells, n=3 animals). Control 
wells did not display any membrane staining that could be considered translocation (0/32 cells). 
To determine whether the 24-hour culture paradigm was obstructing PKCα function and 
preventing translocation from occurring, we cultured dissociated neurons for only 1.5 hours prior 
to starting the experiment. Interestingly, PKCα demonstrated membrane localization in some 
control coverslips with this shorter incubation time, perhaps as a result of the dissociation 
procedure (Figure 9B). Stimulation with PMA did not induce further translocation of PKCα in the 
1.5-hour culture, presumably because PKCα was already translocated to the membrane. In the 
50B11 cell line, PMA was highly effective in translocating PKCα to the membrane (data not 
shown). These data indicate that translocation of the PKCα isozyme can be induced in cell lines 
and under conditions traumatic to primary DRG neurons. Neurons cultured overnight appear to be 
resistant to PMA-evoked translocation of PKCα. A possible explanation for this difference may 
be that PKCα is sequestered by scaffolding proteins that are not present in the 50B11 cell line.  
 
p-SercPKC staining as an assay for cPKC activity in sensory neurons 
Identification of substrate proteins unique to individual PKC isozymes, or even to PKC families, 
is technically challenging. However, consensus phosphorylation motifs for most PKC isozymes 
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have been identified in most substrate proteins. cPKC isozymes phosphorylate serine or threonine 
residues flanked by arginine or lysine at the -2 and +2 positions and a hydrophobic residue at the 
+1 position (Nishikawa et al., 1997). To investigate the substrates phosphorylated by PKCα, we 
took advantage of a recently produced antibody that selectively binds phosphorylated serine 
residues in this configuration (p-SercPKC). In DRG sections from naïve mice, basal p-SercPKC 
staining was evident in a subset of small diameter neurons, suggesting tonic activity of cPKC 
isozymes in some sensory neurons (Figure 10A). Double-labeling with the p-PKCα antibody 
showed almost perfect overlap between p-SercPKC and PKCα, with over 98% of pSercPKC-positive 
neurons also positive for p-PKCα (482/491 p-SercPKC neurons; n=3 mice). Intense staining was 
also present in primary afferent central projections in the superficial dorsal horn, closely matching 
the distribution of IB4-positive terminals (Figure 10B). As the PKCβII antibody was produced in 
the same host species as the p-SercPKC antibody, we could not determine the extent of co-expression 
between the two. However, the limited overlap between PKCα and PKCβII, the restriction of 
PKCβI to large-diameter neurons and the nearly complete overlap between p-PKCα and p-SercPKC 
suggest that most or all of the basal p-SercPKC staining is mediated by PKCα, suggesting the 
possibility that some portion of available PKCα is constitutively active in virtually all DRG 
neurons expressing this isozyme. 
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Figure 10: Staining for proteins phosphorylated by conventional PKC isoforms is present in 
PKCα neurons. Sections of L2-L5 dorsal root ganglia (A) and dorsal horn (B) were stained with 
the p-SercPKC antibody, which detects proteins that have been phosphorylated by cPKC isoforms. 
p-SercPKC staining overlaps almost completely with PKCα (A, 98%, 482/491 p-SercPKC cells also 
express PKCα). n=3 animals.  
 
To verify the selectivity of the p-SercPKC antibody, dissociated DRG neurons were exposed 
to PMA or vehicle in the presence or absence of two PKC inhibitors with differing selectivity for 
PKC isozymes. GF109203X (reported IC values of 8.4nM for PKCα, 18nM for PKCβΙ and 
0.132μM for PKCε; used at 1μM in Figure 11A) inhibits cPKCs and PKCε while CGP 53353 
preferentially inhibits PKCβII (reported IC values 0.41µM for PKCβII, 3.8µM for PKCβI; used 
at 4.1μM in Figure 11A). Protein was isolated and p-SercPKC staining was quantified by slot blot 
and normalized to total protein. As expected, a 30 min exposure to PMA caused intense staining 
in DRG protein samples (Figure 11A). Despite the fact that PMA is a non-selective activator of 
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PKC isozymes, PMA-induced p-SercPKC staining in the presence of the two PKC inhibitors 
combined was not significantly different from unstimulated controls, consistent with selective 
binding by the antibody of p-Ser residues phosphorylated by cPKC isozymes. Intriguingly, 
GF109203X was sufficient to reduce staining intensity due to PMA compared to PMA alone 
conditions, whereas CGP did not decrease PMA-induced p-SercPKC staining intensity (Figure 11A, 
n=3 animals). These results support the selectivity of this antibody for p-Ser residues 
phosphorylated by cPKC isozymes. 
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Figure 11: Proteins phosphorylated by conventional PKC are altered following PKC 
stimulation and CFA-induced inflammation. (A) Effect of the broad PKC activator PMA on 
conventional PKC-mediated protein phosphorylation. PMA produces a substantial increase in 
conventional PKC-mediated phosphorylation in DRG protein samples (top row, 1μg of protein 
sample) as determined using slot blot (p-SercPKC antibody). Administration of both PKC and 
PKCβII inhibitors (GF and CGP, respectively) prevents PMA-induced protein phosphorylation, 
with levels no different than unstimulated controls. Administration of GF+PMA reduced PMA-
induced PKC-mediated protein phosphorylation, whereas CGP+PMA was not different than PMA 
alone. (B) Effect of CFA-induced inflammation on conventional PKC-mediated protein 
phosphorylation. CFA-induced inflammation produces changes in protein phosphorylation in L3-
L5 DRGs up to 14 days post-injection as visualized by western blot. Short-term incubation of 
cultured DRGs with PMA produces substantial changes in conventional PKC-mediated protein 
phosphorylation as visualized by the p-SercPKC antibody. Representative images shown. 
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Next, we used p-SercPKC western blots to determine whether cPKC activity is increased in 
DRG in response to peripheral inflammatory injury (Figure 11B). L3-5 DRG were collected at 
times after CFA injection into the hindpaw (day 1, 3, 7 10 and 14 post-CFA). Western blots 
indicate an increase in total PKCα protein on day 3 and 7 in response to CFA, suggesting that the 
increase in cPKC activity was due in part to increased expression of PKCα ( n=6 animals for each 
day post-CFA).  
 
PKCα is an important downstream effector for P2Y1 receptor-mediated mechanical hyperalgesia 
To determine whether cPKC isozymes contribute to pro-nociceptive P2Y1 signaling, we examined 
the impact of PKC inhibitors on behavioral hyperalgesia produced by injection of 2MeSADP into 
the glabrous hindpaw. We previously reported that hindpaw injection of 2MeSADP produced 
acute heat hyperalgesia in mice (Malin and Molliver, 2010). Administration of 2nmol 2MeSADP 
produced mechanical hyperalgesia that persisted for at least 2 hours (Figure 12A; n=10 animals). 
Co-administration of PKC inhibitors that are selective for PKCα (GF109203X) and PKCβII 
(CGP53353) with 2MeSADP attenuated 2MeSADP-induced hyperalgesia (Figure 12A). When 
2MeSADP and GF109203X were co-injected, the effect was no different than 2MeSADP plus 
both inhibitors, indicating a preferential role for PKCα in the P2Y1 signaling cascade leading to 
mechanical hyperalgesia. Administration of PKCα/PKCβII inhibitors alone did not produce 
changes in behavior (Figure 12B).  
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Figure 12: P2Y1 receptor activation produces mechanical hyperalgesia that is attenuated 
with co-administration of a PKCα inhibitor. Administration of the P2Y1 receptor agonist 
2MeSADP (10nmols/10μl) produces a substantial mechanical hyperalgesia that is detected at 30 
minutes post-injection (~60% paw withdrawal frequency) and persists for 120 minutes (A). Co-
administration of the PKCα inhibitor, GF109203X (84nM), with 2MeSADP attenuates the 
mechanical hyperalgesia seen at 30, 60 and 120 minutes (A). No additional attenuation of 
2MeSADP response is seen when both the PKCα and PKCβII are co-administered with 
2MeSADP. The inhibitors alone produce no change in behavior (B). n=8-10 animals/condition, 
(*) indicates values significantly (p<0.001) different from the vehicle alone group, (+) indicates 
values significantly (p<0.05) different from the vehicle group and (#) indicates values significantly 
different (p<0.001) from the 2MeSADP group as determined by Bonferroni correction after two-
way repeated measures ANOVA. 
2.5 DISCUSSION 
Numerous pro-inflammatory mediators released at the site of an injury act through Gq/11 and Gs-
coupled GPCRs to sensitize nociceptors, including ATP, ADP, bradykinin, histamine, serotonin, 
dopamine, proteases and glutamate (Stone and Molliver, 2009). The canonical Gq/11-coupled 
signaling cascade involves the production of diacylglycerol (DAG) and IP3; the DAG and calcium 
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released from intracellular stores by activation of endoplasmic reticulum IP3 receptors are obligate 
activators of cPKC isozymes. Phosphorylation of targets by PKC has been shown to modulate the 
insertion of ion channels into the plasma membrane, alter gating properties of channels and 
regulate transcription and translation (Cesare et al., 1999, Khasar et al., 1999, Bhave et al., 2003, 
Grosso et al., 2008, Zhang et al., 2011).  
  Characterization of the functional regulation and actions of cPKC isozymes (which include 
PKCα, βI, βII and γ) in peripheral nociceptive transmission has been limited (Olah et al., 2002, 
Zhao et al., 2011), and the majority of investigation to date has been focused on PKCε (Cesare and 
McNaughton, 1996, Khasar et al., 1999, Aksoy et al., 2004, Hucho et al., 2005, Summer et al., 
2006, Velázquez et al., 2007, Cang et al., 2009, Joseph and Levine, 2010). Several previous studies 
have reported the presence of mRNA or protein for conventional PKC isoforms α, βΙ or βΙΙ in 
mouse or rat DRG (Khasar et al., 1999, Ma et al., 2001, Olah et al., 2002); however, this study is 
the first to demonstrate the restricted distribution of PKCα by neurochemical subtype or target 
tissue innervation. PKCγ expression has been reported by multiple labs to be absent from DRG, 
although it contributes to spinal nociceptive processing in a discrete group of neurons at the border 
of dorsal horn laminae II and III (Malmberg et al., 1997). 
Our findings indicate that, of the cPKC isozymes, PKCα, and to a much lesser extent 
PKCβII, is broadly expressed in neurons likely to be nociceptors. PKCα is expressed primarily in 
a population of cutaneous putative nociceptors and appears to contribute to hyperalgesia evoked 
by the Gq/11-coupled purinergic receptor P2Y1, which is similarly enriched in IB4-positive neurons 
(Malin and Molliver, 2010, Molliver et al., 2011). PKCα is almost entirely absent from visceral 
afferents and does not colocalize with two markers that label non-nociceptive C-fibers, TH and 
VGLUT3. PKCβ1 appears exclusively in large diameter neurons, whereas PKCβII displays a more 
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heterogeneous distribution in DRG, although the majority of PKCβII-positive neurons are large in 
diameter.  
Translocation assays are often used to characterize the functional activation of PKC and 
have demonstrated robust translocation to the membrane following stimulation for many PKCs, 
including PKCα (Li et al., 2002, Sweitzer et al., 2004, Mandadi et al., 2011d, Vellani et al., 2013). 
We were surprised to find that PMA, an indiscriminate activator of PKC, did not induce 
translocation of PKCα to the membrane in stably cultured neurons, although robust translocation 
of PKCa did occur in neurons acutely in response to dissociation, and in an immortalized neuron-
derived cell line. It is likely that DRG neurons express scaffolding molecules that sequester PKCα 
in a specific location. Several lines of evidence suggest that at least a pool of PKCα in DRG 
neurons is constitutively active and may be perpetually localized to the membrane. First, PKCα 
staining in DRG tissue sections commonly revealed increased fluorescence in the plasma 
membrane, suggesting localization of protein. Second, staining of cPKC substrate proteins in naïve 
DRG sections with the p-SercPKC antibody revealed persistent phospho-staining at baseline in a 
subset of small DRG neurons. Although PKCβI or PKCβII may contribute to this staining, the 
nearly perfect co-localization with PKCα immunoreactivity suggests that this tonic 
phosphorylation is mediated primarily by PKCα and that it is common to virtually all neurons 
expressing this isozyme. This result raises the intriguing possibility that ongoing PKCα activity 
may contribute to the maintenance of nociceptor response properties. 
IB4-positive neurons are nonpeptidergic, ret receptor tyrosine kinase-expressing neurons 
that are essential for the full presentation of noxious mechanical sensation and hyperalgesia; many 
of these neurons are also capable of encoding noxious heat and/or cooling (Molliver et al., 1995, 
Stucky and Lewin, 1999, Vulchanova et al., 2001, Breese et al., 2005, Malin et al., 2006, Molliver 
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et al., 2011, Alvarez et al., 2012). Our finding that PKCα and PKCβII are not expressed in most 
colon and bladder afferents suggests that PKCα signaling does not have a significant impact on 
visceral nociceptive transduction. Notably, IB4-positive neurons represent approximately 75% of 
epidermal innervation and roughly 20% express the heat- and acid-gated channel TRPV1. Many 
sensory afferent C-fibers specialized to detect the exclusively cutaneous sensation of itch are 
included in this population, as are polymodal nociceptors.  
 The preferential expression of PKCα in IB4-positive neurons is significant as these 
neurons represent the majority of cutaneous afferents. Given that PKC isozymes have been 
extensively studied for their ability to sensitize noxious heat transduction through TRPV1, our 
finding that there is only limited expression of PKCβII in IB4-negative small neurons or in GFRα3-
positive neurons indicates that the majority of peptidergic nociceptors are unlikely to express any 
cPKC isoforms (Bhave et al., 2003, Ferreira et al., 2005, Srinivasan et al., 2008). In contrast, PKCε, 
which has been extensively investigated in peripheral nociceptive signaling, is expressed in the 
great majority of DRG neurons (Khasar et al., 1999, Aley et al., 2000, Joseph and Levine, 2010). 
The widespread expression of PKCα in IB4-positive neurons and a minority of GFRα3-positive 
neurons, and the restricted expression of PKCβII, provide a distinct effector for Gq/11 signaling, 
and possibly for other forms of calcium signaling, in these neuronal subsets.  
Several studies in which the peptidergic or nonpeptidergic sensory neuron populations 
were selectively ablated, and in TRPV1 knockout studies, indicated that TRPV1 and the neurons 
expressing this receptor are important for the behavioral expression of heat hyperalgesia but are 
largely dispensable for mechanical hyperalgesia, whereas the IB4/MrgprD population is required 
for the full expression of mechanical hyperalgesia. Our finding that there is only limited expression 
of cPKC in IB4-negative or GFRα3-positive small neurons indicates that the majority of TRPV1-
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expressing nociceptors are unlikely to express any cPKC isoforms (Bhave et al., 2003, Ferreira et 
al., 2005, Srinivasan et al., 2008). This is significant in that TRPV1, and virtually all TRP channels, 
are sensitive to regulation by Gq/11-coupled receptors. In contrast, PKCε, which has been 
extensively investigated in peripheral nociceptive signaling, is expressed in the great majority of 
DRG neurons and has been implicated in the sensitization of TRPV1 by GPCRs (Olah et al., 2002, 
Mandadi et al., 2006, Srinivasan et al., 2008). Notably, visceral afferents include a much higher 
proportion of TRPV1-expressing neurons than do cutaneous afferents (Christianson et al., 2006, 
Christianson et al., 2007). The widespread expression of PKCα and to a lesser extent PKCβII in 
IB4-positive neurons and a minority of GFRα3-positive neurons provides a distinct effector for 
Gq/11 signaling, and possibly for other forms of calcium signaling, in these neuron populations.  
Functional support for the notion that restricted PKC isoform expression provides a 
regulatory mechanism over nociceptor sensitization is demonstrated by a study that used 
isoenzyme-specific PKC knockout mice (Zhao et al., 2011). The PKCα knockout mice in this study 
had no deficits in baseline thermal or mechanical sensitivity and did not display reduced thermal 
hyperalgesia following injection of the inflammatory agent complete Freund’s adjuvant (CFA). 
PKCβ knockout mice did show a decrease in thermal hyperalgesia with CFA injection. Although 
these results appear to conflict with our own interpretation of a role for PKCα in nociceptive 
signaling, several factors indicate that interpretation is more complex. First, we found that PKCα 
is more extensively expressed in IB4-positive than GFRα3-positive neurons, indicating that co-
expression with TRPV1 is limited. Inflammatory thermal hyperalgesia fails to occur in mice 
lacking TRPV1 expression (Caterina et al., 2000), whereas IB4-positive neurons appear to 
contribute more to mechanical hyperalgesia (Cavanaugh et al., 2009), which was not examined in 
Zhao et al. Second, mice in which the IB4+ population were ablated in young animals failed to 
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develop the sensory deficits demonstrated when these neurons were ablated in adult animals. Thus 
there is substantial capacity for developmental compensation in animals with targeted 
manipulations of the nociceptive transduction machinery, such as conventional knockouts, that can 
obscure the role of these afferents in normal pain transmission. In particular, it is unclear whether 
genetic deletion of individual cPKC genes leads to compensatory upregulation of other PKC 
isozymes.  
PKC is thought to contribute to nociceptor sensitization during inflammation by 
translocating to the membrane following activation and phosphorylating membrane-delimited 
substrate proteins including ion channels regulating neuronal excitability (Cesare et al., 1999, Li 
et al., 2002, Sweitzer et al., 2004, Srinivasan et al., 2008, Cang et al., 2009, Mandadi et al., 2011d). 
Thus, our inability to visualize translocation of PKCα to the membrane in DRG neurons, while 
producing robust PKCβII translocation, is surprising. This was not simply a technical failure to 
demonstrate translocation by immunohistochemistry with the available antibodies, as we were able 
to show robust PKCα translocation immediately after neuronal dissociation and in a neuron-
derived cell line (50b11 cell line), suggesting that specific molecular mechanisms prevent 
translocation of PKCα in healthy sensory neurons. It should be noted that the absence of 
discernable translocation did not prevent extensive cPKC substrate phosphorylation in response to 
activation by PMA, as visualized by p-SERcPKC Western blot.  
We have characterized the expression profile of cPKC isozymes in DRG sensory neurons 
and found that PKCα and PKCβII display largely non-overlapping distributions, which suggests 
that these two isozymes have distinct roles in sensory transduction. Furthermore, both PKCα and 
PKCβII-positive afferents show very little innervation of visceral targets, indicating a target tissue-
specific function for these isoforms. Finally, there are indications that the cPKC isozymes, PKCα 
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and PKCβII, are tonically active in basal conditions as demonstrated by the presence of cPKC 
phosphorylated proteins in naive DRG. One possibility is that tonic GPCR activity may result in 
sustained activation of a pool of cPKC in neurons showing constitutive p-SERcPKC staining, which 
was highly correlated with intense PKCα immunoreactivity. Finally, PKCα is a key downstream 
effector of P2Y1-mediated mechanical hyperalgesia, underscoring the importance of PKCα within 
inflammatory pain.  
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3.0  ANTINOCICEPTIVE ACTIONS OF ADP RECEPTORS P2Y12 AND P2Y13 IS 
MEDIATED BY INHIBITION OF ADENYLYL CYCLE IN MOUSE SENSORY 
NEURONS 
3.1 BACKGROUND 
P2Y12 and P2Y13 are Gi/o-coupled members of the P2Y family of nucleotide receptors activated 
by adenosine diphosphate (ADP). We previously demonstrated expression of these receptors in 
sensory neurons of the dorsal root ganglia (DRG). Here, we tested the ability of P2Y12 and P2Y13 
receptors to inhibit adenylyl cyclase (AC), the principal effector mediating nociceptor sensitization 
by inflammatory mediators acting at Gs-coupled receptors. To detect AC activity in sensory 
neurons, we used immunofluorescence densitometry to assess phosphorylation of the cAMP-
responsive element binding protein (CREB). Application of the P2Y12/13 agonist 2 
methylthioadenosine diphosphate (2MeSADP) or P2Y13 agonist inosine diphosphate (IDP) 
significantly reduced CREB phosphorylation evoked by the AC activator forskolin. The magnitude 
of inhibition was comparable to that provided by the µ opioid receptor agonist DAMGO. In vivo, 
2MeSADP reversed behavioral mechanical hyperalgesia evoked by local injection of forskolin, an 
effect that was prevented by P2Y12/13 antagonists. Furthermore, P2Y12/13 antagonists increased 
baseline responsiveness to mechanical stimulation in naïve mice, suggesting that ADP tonically 
modulates nociceptor sensitivity to mechanical stimuli. We propose that ADP signaling through 
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Gi/o-coupled P2Y receptors modulates mechanical responsiveness in nociceptors through 
inhibition of AC and provides endogenous anti-nociceptive signaling during inflammatory pain.  
 
3.2 INTRODUCTION 
Signaling by extracellular nucleotides is mediated by the P2Y family of G protein-coupled 
receptors (GPCRs) and the P2X family of ionotropic receptors. While P2X receptors are activated 
by adenosine triphosphate (ATP), individual P2Y family members are activated by adenosine 
and/or uridine diphosphates or triphosphates (Malin and Molliver, 2010). ATP injection has been 
known to cause pain for more than 30 years (Bleehen and Keele, 1977). More recently, nucleotide 
signaling in peripheral sensory neurons has been implicated in both the acute transduction of 
noxious stimuli and the sensitization of nociceptors in response to injury or inflammation 
(Hamilton et al., 2000, Molliver et al., 2002, Donnelly-Roberts et al., 2008, Malin et al., 2008). 
Despite the current emphasis on excitatory effects of purinergic signaling, P2Y receptors may be 
excitatory or inhibitory, dependent on their coupling to different G proteins. Three potentially 
inhibitory Gi/o-coupled P2Y receptors have been identified: P2Y12, P2Y13 and P2Y14 (Ralevic 
and Burnstock, 1998). These receptors are expressed in sensory neurons of the dorsal root ganglia 
(DRG) and enriched in nociceptors (Malin and Molliver, 2010). P2Y12 and P2Y13 are activated by 
ADP, whereas P2Y14 is a receptor for glycosylated uridine diphosphate (UDPG). The Gq/11-
coupled receptors P2Y1 (activated by ADP) and P2Y2 (activated by both ATP and uridine 
triphosphate (UTP)) are also highly expressed in sensory neurons and contribute to the 
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transmission of noxious thermal and mechanical stimuli (Ralevic and Burnstock, 1998, Malin et 
al., 2008, Dussor et al., 2009, Malin and Molliver, 2010).  
Activation of adenylyl cyclase (AC) by Gs-coupled GPCRs to produce cyclic adenosine 
monophosphate (cAMP) provides a major mechanism for the sensitization of nociceptors and the 
induction of hyperalgesia by peripherally-released inflammatory mediators (Gold et al., 1996, 
Gold et al., 1998, Fitzgerald et al., 1999, Momin and McNaughton, 2009). Furthermore, Levine 
and colleagues have proposed that AC is the key effector in a switch from acute hyperalgesia to 
chronic predisposition to inflammatory pain via a “hyperalgesic priming” mechanism (Reichling 
and Levine, 2009). Endogenous mechanisms regulating AC activity in nociceptors are therefore 
of great interest as potential targets for intervention in chronic pain. In the current study, we 
investigated the ability of Gi/o-coupled ADP receptors to inhibit AC in isolated DRG neurons using 
phosphorylation of the cAMP-responsive element binding protein (CREB) as a biometric. CREB 
is a major downstream phosphorylation target of cAMP-dependent protein kinase A (PKA), a 
regulator of activity-dependent regulation of activity-dependent gene expression (Shaywitz and 
Greenberg, 1999). Finally, we investigated in vivo actions of P2YGi/o receptor agonists in naïve 
mice and in the forskolin model of AC-dependent mechanical hyperalgesia (Carlton et al., 2009).  
3.3 MATERIALS AND METHODS 
Animals 
All experiments were conducted on adult male wild type C57BL6 mice. Mice were housed at 
maximum of 4 per cage in a temperature-controlled environment (20.5 °C). They were provided 
food and water ad libitum and maintained on a 12:12 hour light-dark cycle. All studies were carried 
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out in adherence to the guidelines of the Institutional Animal Care and Use Committee of the 
University of Pittsburgh and the NIH Guide for the Care and Use of Laboratory Animals. 
 
DRG neuron dissociation 
DRG neurons were dissociated essentially as described in (Malin et al., 2007). Mice were 
administered an overdose of avertin anesthetic and euthanized by transcardial perfusion with 
Hanks balanced salt solution (HBSS; Gibco BRL) maintained at 4 ºC. All DRGs were rapidly 
dissected, enzyme-treated and dissociated by trituration. The protocol was modified to increase 
yield by extending the incubation in papain from 10 min to 20 min and minimizing trituration. 
Neurons were then plated on poly-D lysine/laminin-coated coverslips in 6 well culture plates or 
Millipore EZ chamber slides, incubated at 37 ºC for 60-90 min, after which each well was flooded 
with 1-2 ml pre-warmed and equilibrated complete medium containing F12 (Gibco BRL), 10 % 
fetal bovine serum (Invitrogen) and 1 % penicillin/streptomycin (Gibco BRL). Cells were assayed 
16-24 hours after plating. 
 
CREB phosphorylation in forskolin-stimulated DRG neurons 
To determine the effect of P2YGi/o receptor agonists and antagonists on AC in isolated sensory 
neurons we analyzed CREB phosphorylation by immunofluorescence. Dissociated DRG neurons 
were equilibrated in 37 °C calcium-free HBSS for 90 min, pretreated with agonists in the presence 
or absence of antagonists for 10 min and then stimulated with 10 µM forskolin. In some 
experiments, DRG neurons were cultured in the presence of pertussis toxin (PTX; 500 ng/ml for 
24 hrs; Tocris) prior to agonist treatment. P2Y agonists and antagonists were purchased from 
Tocris. 
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Immunocytochemistry  
Following drug administration, dissociated neurons on cover slips were rapidly rinsed in cold 
phosphate buffered saline (PBS), fixed for 10 min in ice cold 4 % paraformaldehyde, treated with 
ice-cold methanol for 10 min and then blocked for 30 min in a solution containing 2 % normal 
horse serum and 0.2 % Triton X-100 in PBS. Coverslips were then incubated overnight in the same 
blocking buffer containing rabbit anti-pCREB antibody (Cell Signaling, 1:1000) followed by 
incubation for 60 min in blocking buffer containing donkey anti-rabbit antibody conjugated to 
CY3 (Jackson ImmunoResearch, 1:500) and mounted on slides with anti-fade mounting medium 
(Dako).  
  
Quantification of CREB phosphorylation 
CREB phosphorylation was evaluated by quantifying the intensity of pCREB immunofluorescence 
using densitometric analysis in ImageJ software. Images of cultured DRG neurons were acquired 
using a Leica DMRX microscope and photographed with a QImaging Retiga 1300 digital camera. 
Four fields were photographed for each coverslip and a minimum of 2 coverslips were counted per 
condition for each experiment. Experiments were performed at least 3 times. Images were 
collected using QCapture software and Adobe Photoshop. All software and illumination 
parameters were held constant for all conditions within each experiment. As CREB protein is 
restricted to the nucleus, each neuron was analyzed individually by selecting the entire nucleus as 
a region of interest in the software to provide the mean nuclear staining intensity for each neuron. 
Cytoplasmic fluorescence intensity was measured to provide a background reference and 
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subtracted from the nuclear staining intensity. Measurements from all cells examined in each 
condition were averaged and compared between conditions.  
 
P2Y12/13 mediated protein phosphorylation as determined by western and slot blot 
Slot-Blot Assay  
DRGs were isolated and cultured overnight as described previously (Malin et al., 2007). Complete 
media (MEM 10%FBS + Pen/strep) was removed and neurons were incubated with vehicle, 
forskolin (FSK, 10μM) alone, 2MeSADP (100uM) or FSK+2MeSADP. 2MeSADP was pre-
incubated for 10 min, after which FSK was added to the DRGs for 30 min. The drug solution was 
removed, cultures were washed twice with PBS and the reaction stopped by adding 500μL of 10% 
ice-cold TCA. Samples were incubated on ice for 30 min and cells were collected by scraping and 
placed into microfuge tubes. Cells were centrifuged for 10 min at 4oC and the supernatant was 
carefully removed. The pellet was re-suspended in 15-25μL of DiGE buffer (7M Urea, 2 M 
Thiourea, 2% CHAPS 30 mM Tris-HCl at 8.5). 
   PVDF membrane was placed on a manifold, equilibrated in TBS buffer and then washed with 
200 μl TBS per well. All sample solutions were made in 200 μl TBS and applied to the membrane 
using a Bio-Rad Bio-Dot SF vacuum manifold. Wells were then washed twice with at least 200 μl 
of TBS. The membrane was removed and blocked with 2.5% BSA solution made in TBS for 1 
hour at room temperature, washed twice with TBS-T buffer for 10 minutes with gentle agitation 
and incubated in primary antibody solution (p-SerPKA, Cell signaling) overnight at 4°C. The 
membrane was washed in TBS-T three times for 10 minutes with gentle agitation and incubated 
in secondary antibodies conjugated to Cy2, Cy3, or Cy5 (Jackson ImmunoResearch) for 2 hours 
at room temperature, then washed three times again. Fluorescence images were acquired using a 
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FluoChem Q blot imager (Cell Bioscience, Santa Clara CA) or a Typhoon FLA 9500 scanner (GE 
Healthcare, Piscataway NJ) and analyzed by AlphaView or ImageQuant TL Software. Bands were 
quantified by densitometry and normalized to GAPDH or total protein visualized after background 
subtraction. 
Western Blot  
Collected DRGs were collected, frozen immediately on dry ice and homogenized in a 0.5ml tube 
using a plastic pestle in lysis buffer (7 M Urea, 2 M Thiourea, 4% CHAPS, 30 mM Tris-HCl at 
pH 8.5) containing protease and phosphatase inhibitors. The lysate solution was incubated on ice 
for 20 min and centrifuged for 5 min at 10,000g. Supernatant was placed in a fresh tube and stored 
at -20°C. Protein samples were quantified using GE Healthcare 2D Quant kit (GE Healthcare, 
Piscataway NJ).  
   Frozen lysates (20μg) were thawed on ice, mixed with 5X Laemmli loading buffer loaded and 
onto 12% SDS polyacrylamide gels using Mini Gel Tanks (Life Technologies, Grand Island NY). 
Protein was transferred to PVDF membrane with Mini Trans-Blot Cell (Bio-Rad, Hercules CA) 
and incubated with antibodies for fluorescent visualization and quantification as above. GAPDH 
was incubated simultaneously on the same blot as a loading standard. 
 
Mechanical threshold and hyperalgesia testing  
Behavioral data were collected in the Rodent Behavior Analysis Core of the University of 
Pittsburgh Schools of Health Sciences. Mice were placed in individual Plexiglass chambers on a 
mesh platform and acclimated for 60 min at room temperature for 3 days. A depiction of the 
procedures used is shown in Figure 13. 
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Standard von Frey testing: Hindpaw withdrawal frequencies to von Frey mechanical stimulation 
(vF #3.61, equivalent to 0.4g force) were measured as the number of withdrawals out of 10 trials 
per mouse, with 10 withdrawals out of 10 corresponding to a 100% withdrawal frequency. 
Responses were recorded at baseline, 30, 60, 120 min and 24 hr after treatments. Drug solutions 
were made in saline immediately before use for each experiment and the experimenter was blinded 
to the solution being tested. Forskolin (FSK, adenylyl cyclase activator) was used at 10µM/10µl, 
2methylthioadenosine diphosphate (2MeSADP, P2Y12/13 receptor agonist), AR-C66096 
(selective P2Y12 antagonist), MRS2211 (selective P2Y13 antagonist) and MRS2500 (selective 
P2Y1 antagonist) were all used at 10nmols/10µl.  
Simplified up-down method (SUDO): Hindpaw withdrawal threshold was determined using the 
simplified up-down method (SUDO) (Bonin et al., 2014). The mice were presented with 5 stimuli 
(vF # 3.6-4.56) within 5 trials. For the first trial, the middle filament was used. If the animal 
withdrew its paw to the stimulus, a lower force filament would be used for trial #2, and if the 
animal did not withdraw its paw to the filament in trial #1, a higher force filament would be used 
in the subsequent trial. This continues for 5 trials, and the minimum force required for the animal 
to withdraw its paw plus or minus 0.5 g, depending on if the last trial was negative of positive, is 
calculated.  
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Figure 13: von Frey mechanical behavioral testing methods. Paw withdrawal frequency to von 
Frey mechanical stimuli (#3.61, 0.4g) was determined as demonstrated in (A). To determine 
changes to basal paw withdrawal threshold, five von Frey filaments (#3.61-4.56, 0.4-4g) were used 
utilizing the simplified up-down method (SUDO). SUDO chart was adapted from (Bonin et al., 
2014). 
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Statistical analysis 
Data for the CREB phosphorylation assay are presented as mean ± SEM and statistical significance 
was determined using Student’s t-test for single comparisons and ANOVA for multiple 
comparisons. Data for the behavioral experiments are presented as mean ± standard error of the 
mean (SEM). Statistical analyses were performed using two-way repeated measure analysis of 
variance (ANOVA), with the repeated measure being time, followed by Bonferroni post hoc test. 
All data were analyzed using SigmaPlot (version 12.0, Systat Software Inc.). 
3.4 RESULTS 
P2Y12/13 agonists inhibit adenylyl cyclase in DRG neurons 
We previously demonstrated that P2Y12 and P2Y13 are widely co-expressed in small-diameter 
mouse DRG neurons likely to be nociceptors (Malin and Molliver, 2010). Here, we tested whether 
these receptors are capable of inhibiting AC activity stimulated by forskolin in DRG neurons. We 
performed densitometric analysis of forskolin-induced pCREB immunofluorescence in dissociated 
DRG neurons as a measure of AC activation (Figure 14). CREB is a transcription factor that is 
activated by phosphorylation when the AC/cAMP/PKA transduction cascade is activated. 
Application of forskolin produced robust nuclear pCREB immunofluorescence in virtually all 
neurons (Figure 14). Pre-treatment with 100 µM 2MeSADP (a P2Y12/13 agonist), inosine 
diphosphate (a selective P2Y13 agonist in mice), or DAMGO (a µ opioid receptor agonist) for 10 
minutes reduced forskolin-induced pCREB staining intensity by 66.29 ± 5.08, 67.58 ± 3.31 and 
72.87± 2.49%, respectively (Figure 14). 2MeSADP is also an agonist at the Gq/11-coupled P2Y1 
receptor, which might be expected to increase pCREB by increasing intracellular calcium, 
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however previous studies have shown that ADP does not increase CREB phosphorylation in DRG 
neurons (data not shown; (Molliver et al., 2002)). Overnight incubation with pertussis toxin (500 
ng/ml) prevented the inhibitory effects of IDP and 2MeSADP, confirming that inhibition was Gi/o-
mediated. Application of the P2Y13 antagonist MRS2211 reversed 2MeSADP inhibition of 
forskolin-induced pCREB staining by roughly 50% (Figure 14). In contrast, there was no 
significant inhibitory effect of 2MeSADP in the presence of the P2Y12 antagonist AR-C66096 
and reversal of IDP-induced inhibition by MRS2211 was effectively complete, consistent with 
IDP acting solely through P2Y13. Thus, both receptors appear to contribute to the inhibitory effect 
of 2MeSADP. 
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Figure 14: FSK-induced phosphorylation of CREB in DRG neurons. In the absence of 
stimulation, dissociated DRG neurons showed very limited pCREB immunoreactivity (A, 
Control). Intense nuclear pCREB staining was induced by application of forskolin (A, FSK).  Pre-
treatment with 2MeSADP caused a dramatic reduction in intensity of pCREB staining (A, FSK + 
2MeSADP). Pre-incubation with pertussis toxin eliminated the effects of 2MeSADP on FSK-
mediated pCREB intensity (B). Co-administration of P2Y12 and P2Y13 antagonists (ARC66096 
and MRS2211, respectively) with 2MeSADP blocked the effect of 2MeSADP on FSK-mediated 
pCREB intensity (C). 
P2Y12/13 receptors inhibit PKA-mediated protein phosphorylation 
We used p-SerPKA western blots to determine whether PKA-mediated protein phosphorylation is 
altered by P2Y12 and P2Y13 receptor activation (Figure 15A). A 30 minute FSK (PKA activator) 
treatment of dissociated DRG neurons produced a substantial increase in PKA-mediated protein 
phosphorylation, which could be attenuated with pre-incubation of the P2Y12 and P2Y13 agonist 
2MeSADP (n=4 animals). Slot blot analysis demonstrated an increase in PKA-mediated protein 
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phosphorylation following FSK incubation (Figure 15B) and the ability of P2Y12 and P2Y13 
receptors to attenuate this increase (n=2 animals). 
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Figure 15: P2Y12/P2Y13 activation attenuates FSK-mediated protein phosphorylation. 
(A) Western blot analysis of P2Y12 and P2Y13-mediated attenuation of FSK-induced protein 
phosphorylation. Administration of FSK (adenylyl cyclase activator) produces a substantial 
increase in phosphorylated proteins in dissociated DRG neurons as detected by the p-SerPKA 
antibody. Administration of P2Y12/P2Y13 agonist, 2MeSADP, with FSK (FSK+2MeSADP) 
substantially reduces FSK-mediated protein phosphorylation. (B) Slot blot analysis of P2Y12 and 
P2Y13-mediated attenuation of FSK-induced protein phosphorylation in DRGs. FSK 
administration produces an increase in phosphorylated protein (see 3rd column from right), an 
effect that is attenuated by 2MeSADP application. Rows show increasing protein loading amounts 
(increases from left to right). Representative images are shown. 
 
P2Y12/13 receptor activation reverses forskolin-evoked hyperalgesia  
Paw withdrawal frequencies to mechanical stimulation were measured in mice injected in the 
plantar hindpaw with forskolin (10 µM/10 µl) or vehicle. Forskolin caused a significant increase 
in paw withdrawal frequencies that peaked at 60 min and was still evident at 2 hours, resolving 
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within 24 hours (Figure 16). Concurrent treatment of mice with 2MeSADP (10 nmol/10µl) with 
forskolin completely prevented mechanical hyperalgesia and mice were not different from vehicle 
controls at any time point. When AR-C66096 (P2Y12 antagonist) and MRS2211 (P2Y13 
antagonist) were included in the injection with 2MeSADP and forskolin, the anti-hyperalgesic 
action of 2MeSADP was eliminated at 30 min post injection, supporting an action of P2Y12/13 in 
the reversal of AC-mediated mechanical hyperalgesia. Doses for FSK and 2MeSADP were 
determined based on Figure 17. 
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Figure 16: P2Y12/13 receptors inhibit forskolin-mediated mechanical hyperalgesia. 
Activation of adenylyl cyclase with forskolin (FSK) produces a significant increase in paw 
withdrawal frequency that can be attenuated with the P2Y12/13 receptor agonist 2MeSADP. 
Selectivity of 2MeSADP for the P2Y12/13 receptor is demonstrated when co-injection of 
P2Y12/13 antagonists with FSK and the P2Y12/13 agonist 2MeSADP prevents effects of 
2MeSADP at the 30 min time point. Asterisks (*) indicate p<0.05 compared to vehicle and pluses 
(+) indicate p<0.05 compared to FSK, as determined by two-way repeated measures ANOVA with 
Bonferroni post-hoc correction. n=10 animals/condition. 
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Figure 17: Forskolin (FSK) and 2MeSADP behavioral dose response. Dose response curves 
for FSK, the adenylyl cyclase activator, and 2MeSADP, the P2Y12/13 antagonist. Effects of FSK 
10µM injection into the hindpaw (A) were attenuated with all three 2MeSADP doses tested (1mM, 
100μM and 10μM). Only the 2MeSADP 1mM dose (B) was effective at eliciting activity through 
the other ADP-responsive receptor, P2Y1. The vehicle group (not shown) was significantly 
different (p<0.001) at the 30 min, 60 min and 120 min time points with the FSK 10uM and 
2MeSADP 1mM groups only. No other groups were different compared to vehicle treatment at 
any time point. Asterisks (*) indicate p<0.05 (±SEM) compared to 2MeSADP 10uM and pluses 
(+) indicate p<0.05 (±SEM) compared to FSK alone, as determined by two-way repeated measures 
ANOVA with Bonferroni post-hoc correction. n=10 animals/condition for FSK alone and 
2MeSADP 1mM groups, n=5 animals/condition for remaining groups. 
P2Y12/13 modulate baseline mechanical responsiveness 
The ability of P2Y12/13 to inhibit mechanical hyperalgesia produced by activation of AC raised 
the question of whether P2Y12/13 activity may participate in setting the basal mechanical 
sensitivity of primary afferents, in what we have referred to as “nociceptive tone”. To examine this 
issue, withdrawal frequencies to mechanical von Frey stimulation were measured in a separate 
cohort of mice, which then received hindpaw injections of AR-C66096 and MRS2211 as above 
(Figure 18A). No spontaneous nocifensive behaviors were observed in response to injection of 
the antagonists (licking, guarding or biting of the injected paw), however there was a significant 
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increase in paw withdrawal frequency to mechanical stimulation that peaked at 30 min post-
injection and resolved by 120 min. (Figure 18A). Inhibition of the P2Y1 receptor with MRS2500 
produced hypoalgesia at 60 min and 24 hours post-injection, demonstrating that P2Y1 was active 
at baseline as well (Figure 18B). 
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Figure 18: ADP receptor signaling occurs in basal states. Inhibition of all three ADP-responsive 
receptors, P2Y1, P2Y12 and P2Y13, at baseline produced mechanical behavior phenotypes. (A) 
P2Y12/13 inhibition with MRS2211 and AR-C 66096 produces an increase in paw withdrawal 
frequency at 30 min and 60 min post-injection, indicating P2Y12/13 receptors are tonically active 
and dampen nociceptive signaling. (B) Inhibition of the P2Y1 receptor with MRS2500 increases 
paw withdrawal threshold at 60 min and 24 hr post-injection, suggesting P2Y1 receptors are active 
at baseline and facilitate nociceptive signaling. Asterisks (*) indicate p<0.05 (±SEM) compared to 
vehicle, as determined by two-way repeated measures ANOVA with Bonferroni post-hoc 
correction. n=8-10 animals/condition. 
3.5 DISCUSSION 
In the experiments described here, we provide evidence that P2Y12 and P2Y13 inhibit AC activity 
in sensory neurons and reverse mechanical hyperalgesia evoked by activation of AC in vivo. 
Furthermore, antagonists of these receptors increase sensitivity to mechanical stimulation in naïve 
mice, suggesting that P2Y1/P2Y12/P2Y13 receptors tonically modulate nociceptor 
responsiveness. These findings provide evidence that ADP signaling through P2Y12/13 receptors 
represents an endogenous anti-nociceptive mechanism that antagonizes the sensitizing effects of 
pro-inflammatory mediators and may contribute to the resolution of inflammatory hyperalgesia. 
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AC as a lynchpin for the modulation of nociceptive signaling 
Roles for the AC/cAMP/PKA transduction pathway in primary nociceptor sensitization have been 
firmly established (Hucho and Levine, 2007). Numerous pro-inflammatory mediators and 
cytokines are capable of sensitizing nociceptors in animals and humans by acting at neuronal Gs-
coupled receptors. These inflammatory mediators include prostaglandins, serotonin, dopamine, 
adenosine, epinephrine and others (Reichling and Levine, 2009, Stone and Molliver, 2009). As a 
result of AC activation by Gs-coupled receptors, PKA enhances the function of multiple channels 
directly contributing to nociceptive transmission, including NaV1.8 (tetrodotoxin-resistant sodium 
channels), HCN channels (responsible for the I(h) current), TRPV1, P2X3 and NR1 (Hamilton et 
al., 1999, McCleskey and Gold, 1999, Mohapatra and Nau, 2003, Momin and McNaughton, 2009).  
Furthermore, Levine and colleagues have implicated AC in a molecular switch that 
predisposes animals to exaggerated mechanical hyperalgesia as a result of a prior, “priming” injury 
(Reichling and Levine, 2009). This switch allows AC to signal through the exchanger protein Epac 
as well as PKA, activating the protein kinase C pathway to drive further enhancement of the 
signaling machinery in nociceptors. This mechanism has been proposed to represent a molecular 
substrate for the transition from acute to chronic pain. Given that hyperalgesic priming is sustained 
by AC, our results suggest that drugs targeting P2YGi/o receptors should be efficacious in chronic 
pain conditions driven by inflammatory priming.  
 
Actions of Gi/o-coupled P2Y receptors in sensory neurons 
Gi/o–coupled receptors are the focus of numerous studies in the pain field, historically with heavy 
emphasis on opioid receptors and more recently metabotropic glutamate receptors (Sluka and 
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Audette, 2006, Carlton et al., 2009, Govea et al., 2012). Canonical signaling pathways for Gi/o-
coupled receptors include inhibition of adenylyl cyclase (AC) and voltage-dependent calcium 
channels, as well as activation of G protein-coupled inwardly rectifying potassium channels 
(GIRKs) (Stone and Molliver, 2009). Gerevich et al. reported that Gi/o-coupled ADP receptors 
inhibit voltage-dependent calcium channels in dissociated DRG neurons (Wirkner et al., 2004). 
We and colleagues recently demonstrated that P2Y12-14 are expressed in DRG neurons, where 
they are enriched in putative nociceptors (Malin and Molliver, 2010). Agonists for these receptors 
inhibited depolarization-evoked calcium influx in sensory neurons in vitro and reversed 
hyperalgesia in a model of inflammatory pain in vivo (injection of CFA into the hindpaw). Like 
AC, calcium flux regulates neuronal response properties through actions on the existing 
transduction machinery (e.g., through activation of calcium-calmodulin dependent kinase, protein 
kinase C and calcineurin) regulation of activity-dependent gene expression, and modulation of 
neurotransmitter release (both peripherally and at the central synapse). The observations that 
P2Y12/13 inhibit both voltage-dependent calcium influx (Malin and Molliver, 2010) and AC 
activity (reported here) suggest that these receptors exert a powerful inhibitory influence in sensory 
neurons. Although the behavioral paradigm used here produces mechanical hyperalgesia evoked 
by activation of AC, presumably both of these actions of P2Y12/13 contribute to their 
antihyperalgesic efficacy. Whether these receptors also activate GIRKs in DRG neurons remains 
to be determined. 
Although in this study we used CREB phosphorylation primarily as a reporter of AC 
activity, it is important to note that CREB is a key activity-dependent transcription factor that is 
likely to contribute to transcription underlying enhanced nociceptive transmission in primary 
afferents. A broad array of genes are positively regulated by CREB (Zhang et al., 2005) (See also 
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the CREB Target Gene Database by these authors: http://natural.salk.edu/CREB/); these include 
genes with a clearly defined role in nociceptive signaling, such as glutamate receptors, brain-
derived neurotrophic factor (BDNF), calcitonin gene-related peptide (CGRP) and tachykinin-1 
(the gene for substance P). Thus, it is possible Gi/o-coupled receptors that inhibit AC, such as 
P2Y12/13, inhibit nociceptive transmission both by limiting the cAMP-dependent regulation of 
the existing signaling machinery and by limiting activity-dependent gene expression in peripheral 
nociceptors, the latter of which may be particularly important for chronic pain syndromes.  
 
Nucleotide release from peripheral tissues 
Stimulus-evoked release of ATP has been demonstrated for diverse cell types, including both 
cutaneous and visceral epithelial cells, and release is enhanced in response to tissue injury in 
multiple models (Burnstock, 1999, Zhao et al., 2008, Dussor et al., 2009, Mandadi et al., 2009). 
Several groups have proposed that keratinocytes contribute to the sensory transduction of thermal 
and/or mechanical stimuli by releasing ATP in response to stimulation, which then activates P2 
receptors on sensory neurons. ATP is hydrolyzed by the NTPDase family of ectonucleotidases. 
These enzymes determine the availability and half-life of extracellular ATP, ADP and AMP. In 
nociceptive circuits, we found that the principle ectonucleotidase is NTPDase3, which hydrolyzes 
ATP to ADP rapidly, but ADP to AMP more slowly, likely results in the rapid termination of ATP 
signaling followed by more prolonged ADP transmission (Vongtau et al 2011). These 
characteristics suggest a model in which ATP is constitutively released at low levels by peripheral 
tissues, persistently at higher levels during inflammation, and acutely at high levels in response to 
a strong or noxious stimulus. Consistent with this model, ATP receptors are excitatory (either 
ionotropic P2X or metabotropic Gq-coupled receptors), whereas ADP receptors are either 
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inhibitory P2Y12-14 or excitatory (P2Y1). P2Y6 is another Gq-coupled diphosphate receptor 
(selective for uridine diphosphate), but does not appear to be widely expressed in sensory neurons 
(Stucky et al., 2004, Malin et al., 2008). However, there is some evidence that persistently high 
levels of ATP may desensitize P2 receptors, underscoring the importance of NTPDases in the 
regulation of P2 receptor signaling (Mizumoto et al., 2002, Mense, 2009). 
 
Acute vs tonic modulation of nociceptor sensitivity 
Carlton and colleagues previously demonstrated that Gi/o-coupled metabotropic glutamate and 
somatostatin receptors inhibit TRPV1 function and thermal hyperalgesia (Carlton et al., 2004, 
Carlton et al., 2009, Govea et al., 2012). Intriguingly, Gi/o-coupled somatostatin receptors, but not 
glutamate or opioid receptors, appear to tonically modulate nociceptor function (Carlton et al., 
2001). Our results suggest that P2Y12/13 receptors tonically modulate basal mechanical 
responsiveness in nociceptors, as local injection of antagonists in naïve mice increased sensitivity 
to von Frey mechanical stimulation. Deficits in basal thermal and mechanical thresholds were also 
reported in mice lacking adenylyl cyclase 5 (AC5), a finding consistent with a role for cAMP 
signaling (and inhibition of cAMP production by Gi/o-coupled receptors) in the tonic modulation 
of sensory neuron responsiveness (Kim et al., 2007). Pursuing this idea further, it seems logical to 
suggest that Gi/o-coupled receptors that affect basal response thresholds have some ongoing 
activity that modulates steady-state AC activity levels. Tonic but variable release of ATP by 
peripheral tissues may provide a mechanism by which nociceptors monitor homeostatic changes 
in their target tissues (Lazarowski et al., 2003, Lumpkin and Caterina, 2007, Dussor et al., 2009). 
Opioid receptors represent the prototypical Gi/o-coupled receptors, and opioid agonists 
represent some of the oldest and most extensively used analgesic drugs. Opiates are often effective 
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in the treatment of inflammatory pain, but are associated with potentially severe side effects that 
limit extended use, including tolerance, respiratory suppression and gastrointestinal constipation, 
and the potential for addiction and abuse. Opioid agonists inhibit peripheral nociceptive signaling, 
as well as having central effects, by inhibiting voltage-dependent calcium channels and AC, similar 
to our results with P2YGi/o receptors (Schroeder et al., 1991, Vetter et al., 2006). Our in vitro and 
in vivo findings indicate that P2YGi/o receptors have anti-hyperalgesic actions mediated in part by 
inhibiting AC. Combined with previous results indicating that these receptors also reduce calcium 
signaling in nociceptors, our findings provide strong evidence that P2YGi/o receptors provide 
endogenous anti-nociceptive signaling driven by extracellular nucleotides and may represent 
productive targets for the development of novel analgesics. Such drugs could potentially be used 
either on their own, or as adjuvants with opiates to reduce the required opiate doses and minimize 
their deleterious side effects.
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4.0  GENERAL DISCUSSION 
Given the importance of purinergic signaling in modulating the inflammatory response, I set out 
to characterize three key ADP-responsive purinergic receptors, P2Y1, P2Y12 and P2Y13, in order 
to better understand how they could contribute to pain. The goals of this dissertation were to: 
(1) Determine the PKC isoforms that P2Y1 receptors signal through, determine the 
expression pattern of PKC isoforms in dorsal root ganglion neurons and where these 
dorsal root ganglion neurons project. 
(2) Investigate the effects of PKC isoform-specific inhibition on P2Y1-mediated 
behavioral hypersensitivity.  
(3) Identify key downstream signaling components of P2Y12 and P2Y13 receptors and the 
effects of P2Y12/P2Y13 inhibition on adenylyl cyclase-mediated mechanical 
hypersensitivity. 
Current literature on purinergic receptors in the peripheral inflammatory response focuses 
primarily on ionotropic P2X purinergic receptors, with little focus on the metabotropic P2Y 
purinergic receptors. Work from our laboratory indicated that the P2Y1 receptor potentiates 
peripheral inflammation-induced hypersensitivity whereas P2Y12 and P2Y13 receptors attenuate 
this hypersensitivity (Malin and Molliver, 2010). What remains elusive are the exact downstream 
components that comprise the signaling cascades of P2Y1, P2Y12 and P2Y13- information that is 
critical for furthering our understanding of these three receptors. 
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 We discovered that P2Y1 signaling relied primarily on the conventional PKC isoform, 
PKCα, to produce peripheral mechanical hypersensitivity. Interestingly, our work demonstrated 
that PKCα was co-expressed in the same population of nociceptors as the P2Y1 receptor, the IB4 
population. Additionally, PKCα expressing dorsal root ganglion neurons primarily projected to 
cutaneous targets, and not visceral, indicating a peripheral role for PKCα. Work from this 
dissertation demonstrated that P2Y12 and P2Y13 receptors act through PKA to modulate target 
proteins and P2Y12 and P2Y13 receptors provide significant anti-nociceptive drive to the adenylyl 
cyclase pathway. Finally, we found that all three receptors, P2Y1, P2Y12 and P2Y13, are active 
at baseline and provide a basal nociceptive tone. These findings raise interesting questions 
regarding P2Y1, P2Y12 and P2Y13 receptor function and their role in modulation of pain and 
warrant further investigation. 
4.1 THE P2Y1 RECEPTOR AND SELECTIVITY FOR CONVENTIONAL PKC 
ISOFORMS 
Activation of the Gq-coupled P2Y1 receptor leads to production of diacylglycerol and release of 
calcium, both of which are required for conventional PKC activation (Figure 2 and Figure 3). In 
chapter 2.0 of this thesis, I tested the hypothesis that (1) P2Y1 signaling preferentially utilizes 
conventional PKC isoforms in order to have downstream effects and (2) if any preferential 
signaling of P2Y1 through a conventional PKC isoform exists, whether the PKC isoform will be 
co-expressed in similar distributions within the DRG as P2Y1.  
My work demonstrated that out of the three conventional PKC isoforms expressed in 
mouse dorsal root ganglion neurons, PKCα, PKCβI and PKCβII, PKCα was found to be co-
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expressed in the IB4 population with the P2Y1 receptor. This co-expression was the first indicator 
of a selective relationship between P2Y1 and PKCα within dorsal root ganglion neurons. PKCβI 
was present in large diameter cells and therefore excluded from further investigation. Additionally, 
I found that the majority of PKCα-expressing DRGs project to the skin, and not visceral targets 
such as bladder and colon. Single-cell PCR analysis confirmed the enrichment of PKCα mRNA in 
the MrgprD/IB4 population. Afferents innervating the hindpaw also demonstrated substantial 
PKCα expression, whereas PKCβII was only found in a small number of DRGs innervating the 
skin and was present in a few visceral-innervating DRGs. Both P2Y1 and PKCα are co-expressed 
in a largely cutaneous innervating population, the IB4+ population, so the predominance of PKCα 
in cutaneous-projecting DRGs was expected. However, the restriction of PKCα expression to 
cutaneous afferents almost exclusively over visceral afferents was surprising as it indicates a 
purely non-visceral role for PKCα. The implications of this narrow expression profile for PKCα 
are significant as they suggest a mechanism of activation that is unique to non-visceral DRG 
neurons; PKCα has the potential to be important in Gq-coupled signaling cascades, not just with 
the P2Y1 receptor, that are investigated in peripheral pain. PKCα could also be a useful first line 
measure when studying Gq-coupled signaling in peripheral pain, given the likelihood that PKCα 
is exclusively involved in non-visceral functions. While my expression results point to a specific 
role of PKCα in cutaneous innervating afferents, it does not provide conclusive evidence of the 
functional role for PKCα within these afferents or in peripheral pain.  
In the second part of chapter 2.0 , I investigated the functional role of PKCα and PKCβII 
using cultured DRGs and behavioral models. The importance of using primary cells cannot be 
overstated, as the activation and shuttling of PKCs requires specific chaperones and adapter 
proteins (Mochly-Rosen and Gordon, 1998, Faux et al., 1999). Using cell lines, while informative, 
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does not address the complex nature of PKC signaling or the importance of tissue specific 
functions for the various PKC isoforms. My first aim was to confirm the generally accepted idea 
that activation of PKCs is synonymous with membrane translocation, as is often seen in literature 
from cell lines. Surprisingly, I discovered that PKCβII translocates to the membrane with the broad 
PKC activator, PMA, and with the P2Y1 receptor agonist 2MeSADP whereas PKCα does not 
translocate with either stimulus. Concentration of stimuli and stimuli duration (from 30 seconds to 
1 hour) had no effect on PKCα translocation, though astonishingly DRGs that were cultured only 
briefly after dissociation showed some basal PKCα translocation. I attempted to discover the 
mechanism behind PKCα translocating in short culture conditions but not in 24 hour culture 
condition; my hypothesis was that in the freshly cultured DRGs, there was an increase in 
intracellular calcium due to the nature of DRG dissociation. I found that applying a depolarizing 
high potassium solution or the ionophore Ionomycin, both of which lead to intracellular calcium 
increase and activate PKCs, had no effect on PKCα translocation. Co-applying PMA and the high 
potassium solution also had no effect on PKCα translocation. Thus, the only instances where I was 
able to translocate PKCα was in short culture conditions in DRGs and in the 50b11 cell line, 
indicating that PKCα is capable of translocation but that PKCα translocation is not directly related 
to activation. PKCβII, on the other hand, was able to translocate in a variety of conditions hinting 
at differences in regulation and activation between PKCβII and PKCα.  
To demonstrate that PKCα was being activated in my experimental models despite the lack 
of visually confirmed translocation, I used the p-SercPKC antibody that detects conventional PKC-
mediated protein phosphorylation. This line of experiments demonstrated that (1) the p-SercPKC 
antibody likely detects proteins phosphorylated primarily by PKCα and (2) that PKCα is activated 
in my culture conditions despite the lack of apparent translocation. It is possible that PKCα, unlike 
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the other PKC isoforms, is already present in some quantity at baseline at the membrane and 
therefore does not require substantial recruitment of additional PKCα to produce effects. This line 
of reasoning is supported by my immunohistochemical data, where PKCα labeling in DRGs was 
located in the membrane as opposed to the largely cytoplasmic localization of PKCβII. 
Additionally, it is possible that relatively little PKCα is required at the membrane to have 
significant impact on protein function/phosphorylation. PKCβII, for example, translocated readily 
to the membrane following stimulation despite having little effect on protein phosphorylation. 
These results raise important questions regarding how PKC function is addressed in the literature, 
given that the standard tool used for PKC activation is to look at translocation and my work has 
demonstrated that activation and translocation are not synonymous.  
Given the specific stimuli needed to translocate PKCα, it is possible that this PKC isoform 
is important only during certain inflammatory or injury states. Work from Gereau et. al. supports 
this possibility as only in certain behavioral models were PKCα knockout mice shown to have 
deficits (Zhao et al., 2011). Furthermore, the ability to easily translocate PKCα in the 50b11 cell 
line but not DRGs suggests vastly different regulatory/chaperoning machinery between the two 
cell types. The implication of these results is that there are clear differences in how PKC isoforms 
respond in different cell types and possibly inflammatory/injury states, and any future studies that 
study PKCs in pain should (1) confirm PKC activation occurs concurrently with translocation and 
(2) ensure cell line work can be recapitulated in DRGs or relevant primary cell types. 
4.1.1 Future directions 
Work from my lab has previously demonstrated the importance of P2Y1 receptors in the CFA 
model of inflammatory pain and thus my goal was to elucidate the P2Y1 signaling cascade member 
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PKC (Malin and Molliver, 2010). My results from chapter 2.0 address key questions that have not 
been thoroughly investigated in the pain field. 
(1) Which conventional PKC isoforms are crucial for P2Y1 receptor signaling? 
(2) Where are these PKC isoforms expressed and what is their functional role within 
DRGs? 
I discovered that PKCα, like P2Y1 receptors, is expressed in the nonpeptidergic IB4+ population 
and that PKCα activation is not directly tied to translocation, as previously assumed. A 
shortcoming of the latter finding is that I was unable to track this translocation in real-time and 
relied on fixing stimulated DRGs at various time-points. One of the main concerns with this 
method is the potential for fixation artifacts and possibly missing key translocation events due to 
my choice in time-point intervals. A method to overcome this limitation is to transfect a GFP-
tagged PKCα into dorsal root ganglia neurons and use confocal microscopy to track cellular 
localization of PKCα following stimulation in real time. I have had prior success transfecting 
DRGs with a cAMP-FRET sensor by using a Lonza transfection system and kit. Using this method 
would allow for live-tracking PKCα in primary cells, which allows for testing a wide array of 
stimulation conditions and time points. A downside is that a thorough investigation must first be 
done to ensure that the bulkiness of the GFP tag and overexpression of GFP-PKCα within DRGs 
do not hamper normal PKCα function.  
My immunohistochemical and single-cell PCR data both indicated the preferential 
expression of PKCα in the IB4+ population and the near lack of PKCα in visceral projecting DRGs, 
however I was unable to pursue the functional significance of this expression. In order to continue 
this work, genetically modified mice could be used to study population specific PKCα effects. For 
example, MrgprD is expressed in the IB4+ population and presently, Mrgprd-cre mice exist. Using 
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cre-lox technology, I could produce inducible PKCα knockout in the IB4+ population. By using 
this method, I could ensure that the effects of PKCα inhibition are mediated by DRGs and not 
inflammatory or accessory cells. Additionally, I could specifically target peripheral cutaneous 
nociceptors. It is likely that other cells types implicated in peripheral sensation and inflammation 
express PKCα, and therefore the MrgprD-PKCα mouse provides several distinct advantages.  
Another use of the MrgprD-PKCα mice is to test whether basal behavioral thresholds are 
altered, as I found constitutive membrane localization of PKCα in my immunohistochemical data 
and that could mean constitutive activation of PKCα. While I used the PKCα inhibitor in basal 
states and found no difference in mechanical sensitivity, I could not control for off-target effects 
that are possible with injecting an inhibitor into hindpaw, as inflammatory cells, keratinocytes and 
afferents could all contribute to the behavioral phenotype produced. Additionally, administration 
of the PKCα inhibitor could produce a floor effect with behavior that occludes further analysis. 
Therefore, there is greater certainty regarding specificity with the MrgprD-PKCα mice compared 
to the PKCα inhibitor. A downside of using the MrgprD-PKCα mice is that I would have a 
permanent knockout of PKCα, which could lead to compensatory changes from the other PKC 
isoforms. 
 The combination of using tagged sensors to better assess PKCα function and transgenic 
mice to determine DRG population-specific effects would allow for a complete characterization 
of PKCα within the P2Y1 signaling cascade.   
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4.2 CHARACTERIZATION OF P2Y1 SIGNALING AND IMPLICATIONS FOR 
INFLAMMATORY STATES 
The P2Y1 receptor has previously been implicated in the CFA inflammatory model, with P2Y1KO 
mice and P2Y1 receptor-inhibited mice showing decreased thermal hypersensitivity (Malin and 
Molliver, 2010, Jankowski et al., 2012). P2Y1KO mice also show decreased basal thermal 
sensitivity, further implicating the P2Y1 receptor as a major contributor to thermal sensation 
(Molliver et al., 2011). A key downstream effector for P2Y1, PKC, has also been implicated in 
various inflammatory models. Work from several groups has demonstrated not only that PKC is 
important in pain hypersensitivity but that there are PKC isoform-specific roles in inflammatory 
pain. For example, PKCε is critical for induction of hyperalgesic priming and several other PKC 
isoforms are important for CFA-induced thermal hyperalgesia (Aley et al., 2000, Zhao et al., 
2011). While these special roles for PKC isoforms have been investigated, there has been no 
explicit test of the P2Y1 signaling cascade and its downstream components in the peripheral 
sensory machinery. In chapter 2.0 , I addressed this issue by investigating the ability of PKCα and 
PKCβII to (1) modulate behavioral P2Y1 receptor effects and (2) phosphorylate target proteins 
after activation.  
We focused on PKCα and PKCβII based on the immunohistochemical data, as the other 
two conventional PKC isoforms (PKCβI and PKCγ) are present only in large diameter cells or not 
present at all in the DRG. We chose to focus on conventional isoforms because they require DAG 
and calcium to activate, both of which are produced by Gq-coupled signaling. However, novel 
PKC isoforms also require DAG to activate and could presumably be activated by the P2Y1 
receptor as well. Indeed, inhibition of PKCα did not completely abolish P2Y1-receptor mediated 
mechanical hypersensitivity indicating other PKC isoforms could be involved. Investigation of all 
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of the PKC isoforms implicated in P2Y1-signaling was outside the scope of this thesis, however 
further study into the extent to which different isoforms are involved would prove informative.  
PKCα inhibition was capable of significantly attenuating P2Y1-mediated mechanical 
hyperalgesia, which combined with my PKCα/P2Y1 co-expression data, highlight the importance 
of PKCα within the P2Y1 signaling cascade. As there is no literature in the pain field investigating 
the P2Y1 signaling cascade, let alone characterizing the involvement of PKCα in this cascade, this 
result provides further evidence of a critical role for PKCα. A potential limitation of this result is 
that while PKCα could mediate P2Y1 receptor effects in basal conditions, a variety of PKC 
isoforms could be activated during inflammatory states. Therefore, within the CFA model for 
peripheral inflammation, it is possible that P2Y1 signaling is more promiscuous and recruits 
various PKC isoforms in order to have its effects. In this case, blockade of PKCα would not 
attenuate CFA-induced hyperalgesia to the same extent as PKCα blockade did with P2Y1-
mediated hyperalgesia.  
Next, I used the p-SercPKC antibody, which only detects proteins that have been 
phosphorylated at a conventional PKC-recognizable site. Interestingly, staining perfusion fixed 
DRG sections with p-SercPKC antibody revealed that PKCα expression overlaps almost completely 
with p-SercPKC expression. This data uncovers two remarkable details concerning PKCα: (1) PKCα 
is likely to be constitutively active given the presence of basal protein phosphorylation and (2) 
PKCα is likely the key conventional PKC isoform in DRGs given that conventional PKC-mediated 
phosphorylated proteins are present preferentially in PKCα-positive neurons. 
In order to determine what targets the P2Y1 receptor acts on, I used the p-SercPKC antibody 
to investigate PKC-induced protein phosphorylation following broad PKC stimulation. I found 
that cPKC inhibition reduced p-SercPKC labeling in DRGs providing further evidence of the integral 
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role for cPKCs in nociceptive neurons. The benefit of using this antibody is that it allows for a 
clear and relatively simple method for assessing conventional PKC activity in both basal and 
inflammatory states. Using a combination of slot and Western blots, changes in the quantity of 
targeted proteins and the proteins themselves can be assessed. A caveat of using this antibody is 
that while all PKCs are ser/thr kinases, meaning they phosphorylate at serine or threonine, the 
flanking residues are what determine the phosphorylation sites for PKCs. The conventional PKC 
family recognizes and phosphorylates numerous sequences, which means that even though the p-
SercPKC antibody was made against multiple consensus binding sequences, the antibody might not 
encompass all of the targets of conventional PKCs (Nishikawa et al., 1997). Therefore, it is 
possible that both PKCα and PKCβII are key players within the DRG and phosphorylate a variety 
of targets, however only the targets phosphorylated at the p-SercPKC antibody sequence are 
detected. Without the ability to create antibodies against all of these specific sequences, it is simply 
not possible to have a comprehensive list of conventional PKC targets. The information that can 
be established with the p-SercPKC antibody is quite important as: (1) there is basal PKCα activity 
as demonstrated by constitutive protein phosphorylation and (2) CFA-induced inflammation 
changes the quantity and proteins that are phosphorylated by PKCα, consistent with increased 
PKCα protein levels.  
4.2.1 Future directions 
My work in chapter 2.0 demonstrated the importance of PKCα in mediating P2Y1 receptor effects 
on mechanical hypersensitivity; PKCα inhibition significantly attenuated P2Y1-mediated 
mechanical hyperalgesia, an effect that was not changed with addition of the PKCβII inhibitor. 
Additionally, PMA-induced conventional PKC-mediated phosphorylation was largely 
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accomplished by cPKCs. Finally, the p-SercPKC antibody that detects conventional PKC-mediated 
protein phosphorylation showed almost a complete overlap in expression with PKCα, suggesting 
that PKCα is involved in tonic signaling.  
Given that PKCα and PKCβII are broadly expressed in most tissue, it is hard to 
conclusively determine where the PKC inhibitors are acting to have their effects. The expression 
data suggests that PKCα is present in the afferents innervating the hindpaw and thus is capable of 
being a downstream effector for P2Y1 receptor function. However, there is no causal link that the 
afferents themselves are mediating the behavioral phenotype. It is possible that neighboring 
immune cells, recruited due to the presence of the P2Y1 receptor agonist, underlie the PKCα 
inhibitory effects on mechanical hyperalgesia. If the effects of PKCα inhibition on behavioral 
phenotypes are by non-neuronal mechanisms, then the co-expression of PKCα and P2Y1 in DRGs, 
while interesting, might not play a significant role in IB4+ cell population mediated effects. 
Confirmation of whether PKCα is involved in neuronal P2Y1-mediated effects will require a 
functional analysis of nociceptors.  
A possible technique to overcome this limitation is to use MrgprD-PKCα knockout mice, 
which only have PKCα eliminated in the IB4+/MrgprD population. This method would allow me 
to directly test whether the preferential expression of PKCα in the IB4+ population has 
implications for either IB4+ cell population effects and/or P2Y1 receptor signaling. Additionally, 
the transgenic mice allow for greater certainty regarding specificity of action compared to the PKC 
inhibitors. Experiments using these mice would involve injecting the P2Y1 agonist or another 
inflammatory agent, such as CFA, into the hindpaw and determining whether these mice display 
altered responses compared to wild type mice due to the absence of PKCα. An additional method 
to tackle the issue of targeting the appropriate cells would be to use siRNA injected directly into 
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the DRG itself (Anesti, 2010). This method would allow me to target DRG neurons, though 
potentially glial cells and any recruited immune cells would also undergo PKCα knockdown. 
However, this technique would allow me to use non-genetically modified mice, which come with 
their caveats and concerns regarding what compensatory mechanisms have occurred because of 
the genetic modification.  
One of the most interesting and unexpected pieces of data from my thesis was the strong 
overlap between PKCα and the proteins phosphorylated by all conventional PKC isoforms. This 
overlap implies that PKCα is involved in tonic signaling in DRG neurons, a novel concept 
considering little to no literature exists on basal PKC activity within nociceptors. Functional 
analysis of tonic PKCα-mediated protein phosphorylation is necessary to conclusively 
demonstrate the role of PKCα within nociceptors, and more specifically, how tonic P2Y1 receptor 
activity contributes to this phenomenon. It is possible that tonic P2Y1 receptor activation 
preferentially activates PKCα within a subset of the DRG neurons, the IB4+ population. As PKCα 
shows selective expression in cutaneous afferents, the entire P2Y1/PKCα signaling cascade could 
be providing a cutaneous afferent-specific tonic function.  
Two-dimensional difference gel electrophoresis (2D DIGE) provides a way to determine 
the effect of both tonic- and inflammation-induced PKCα-mediated protein phosphorylation 
(Viswanathan et al., 2006). DRG samples from naive and inflamed mice would first be 
immunoprecipitated using the p-SercPKC antibody. Then the two samples would be labeled with 
fluorescent markers and separated by size and isoelectric point using 2D-DIGE, which allows for 
a direct comparison of the protein samples. Differences between the samples, whether the 
difference lies in protein abundance or post-translational modifications, can be analyzed with mass 
spectrometry and the proteins of interest identified. If certain proteins undergo PKCα-mediated 
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post-translational modifications due to inflammation, for example, those proteins can be visualized 
on the gel and analyzed. 2D-DIGE provides an incredible tool for determining the downstream 
effects of conventional PKC isoforms.  
The identified targets of PKCα phosphorylation could provide key insights into not only 
P2Y1/PKCα-mediated effects but also provide a target for analgesic intervention. 
4.3 THE P2Y12 AND P2Y13 RECEPTORS AND THEIR ROLE IN ANTI-
NOCICEPTIVE SIGNALING 
In chapter 3.0 of my thesis, I examined the Gi/o-coupled ADP receptors P2Y12 and P2Y13. Our 
lab previously uncovered that Gi/o-coupled purinergic P2Y12 and P2Y13 receptors are expressed 
in small-diameter sensory neurons and that activation of P2Y12 and P2Y13 receptors inhibits 
depolarization evoked intracellular calcium transients, which suggests these receptors attenuate 
sensory transmission in nociceptors (Gerevich et al., 2004, Malin and Molliver, 2010). Fully 
characterizing the functional effects of P2Y12/13 receptor activation in nociceptors is a critical 
first step in assessing the analgesic potential of these receptors. 
 In the first part of chapter 3.0 , my aims were to examine the signaling cascade of the 
P2Y12 and P2Y13 receptors in nociceptors, as no studies currently exist addressing this issue in 
nociceptors. The canonical signaling cascade for these receptors is that activation of P2Y12 and 
P2Y13 inhibits adenylyl cyclase activity and voltage-dependent calcium channels (Figure 2). 
Using the adenylyl cyclase activator, FSK, I assessed the ability of P2Y12 and P2Y13 receptors to 
inhibit adenylyl cyclase activity. I discovered that pre-treatment of cultured DRGs with the P2Y12 
and P2Y13 agonist 2MeSADP reduced FSK-induced changes in pCREB staining. One caveat of 
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using pCREB as a measure of adenylyl cyclase activity is that pCREB is an important activity-
dependent transcription factor (Zhang et al., 2005). Thus, while I used CREB phosphorylation as 
a maker for adenylyl cyclase activity, CREB has separate functions that could also contribute to 
nociception and pain. Because CREB is activated upon PKA-mediated phosphorylation, by way 
of adenylyl cyclase activation, any inhibition of adenylyl cyclase by P2Y12 and P2Y13 receptors 
would alter CREB activity. Therefore, the effects of P2Y12 and P2Y13 receptors could include 
modulation of gene transcription in addition to the canonical inhibition of the adenylyl cyclase 
pathway.  
 In order to determine the effects of P2Y12 and P2Y13 receptors directly downstream of 
adenylyl cyclase, I used a PKA activator in conjunction with an antibody that specifically detects 
proteins phosphorylated by PKA. I discovered that FSK-mediated adenylyl cyclase activation 
produces a robust increase in protein phosphorylation via PKA, which can be inhibited by P2Y12 
and P2Y13 receptor activation. The significance of this finding is that (1) there is a method to 
indirectly assess adenylyl cyclase activity in nociceptors and (2) P2Y12 and P2Y13 receptors can 
modulate adenylyl cyclase activity within nociceptors.  
 In the final segment of chapter 3.0 , my aim was to uncover the role of P2Y12 and P2Y13 
receptors in modulating behavioral responses. Gi/o-coupled receptors inhibit adenylyl cyclase as 
one of their primary actions, and adenylyl cyclase is a key downstream component of Gs-coupled 
signaling. Prostaglandins, which are critical for the inflammatory response, signal through Gs-
coupled signaling and are targeted by non-steroidal anti-inflammatory drugs (NSAIDs). 
Accordingly, the ability to inhibit adenylyl cyclases and dampen Gs-coupled signaling is critical 
for analgesia. Adenylyl cyclases have been investigated in pain literature previously; Levine and 
colleagues implicated adenylyl cyclase as the molecular switch necessary for animals “primed” 
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with a prior injury to experience exaggerated hyperalgesia with subsequent insult (Reichling and 
Levine, 2009). Forskolin activates adenylyl cyclase, a key component of Gs-coupled signaling 
pathways (Figure 2). I found that P2Y12 and P2Y13 receptor activation is capable of significantly 
attenuating adenylyl cyclase-mediated mechanical hyperalgesia (Figure 16), demonstrating a key 
role for P2Y12 and P2Y13. Given that Levine and colleagues implicated adenylyl cyclase in the 
transition from acute to chronic pain in their hyperalgesic priming model, it is highly likely that 
P2Y12 and P2Y13 receptors are effective within this model. Furthermore, work from our lab and 
colleagues have already demonstrated the ability of P2Y12 and P2Y13 receptors to dampen 
thermal hyperalgesia in the CFA model of inflammatory pain. Currently opioid Gi/o-coupled 
receptor agonists are used for treating inflammatory pain and are considered highly effective 
analgesics. However, opioids are associated with severe dose-limiting side effects including drug 
tolerance, suppression of gastrointestinal motility and potential for abuse. The data presented in 
this thesis support a critical role for the Gi/o-coupled P2Y12 and P2Y13 receptors in providing 
endogenous anti-nociceptive drive and targeting these receptors could provide a valuable analgesic 
drug. 
 A limitation of P2Y12 and P2Y13 receptors as analgesics is that the P2Y12 receptor is 
expressed in platelets, and P2Y12 is inhibited by antiplatelet drugs used to treat blood clots in 
coronary heart disease (Savi et al., 2001, Garcia et al., 2011). Therefore, negative side effects could 
also occur with using P2Y12 receptor agonists. However, by precluding those susceptible to blood 
clots and coronary heart disease, P2Y12 receptor agonists could still be efficacious as analgesics. 
Interestingly, the P2Y12 receptor antagonist clopidogrel has been reported to cause arthritic pain 
in some patients, further demonstrating the powerful actions of P2Y12 receptors (Garg et al., 2000, 
Agrawal et al., 2013). The clinical reports of P2Y12 antagonism producing pain phenotypes raises 
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the interesting possibility that there is tonic drive of the P2Y12 (and possibly P2Y13) receptor, 
driven by tonic production of its endogenous agonist, ADP.  
ATP, precursor to the P2Y12/13 receptor agonist ADP, has long been known to be involved 
in autocrine processes in various cell types, including keratinocytes (Burrell et al., 2005, Corriden 
and Insel, 2010). This basal release of ATP is thought to mediate proliferation and apoptosis within 
the keratinocytes, which brings up the interesting idea that the nociceptors innervating the 
epidermis also have access to this tonic ATP release. Dorsal root ganglion neurons express all 
three ADP receptors, as our lab has demonstrated previously, and thus this tonic nucleotide 
presence could provide a basal nociceptive tone within the DRGs (Malin and Molliver, 2010).  
 In the second part of chapter 3.0 , I tested the hypothesis that tonic ATP release onto 
afferents innervating the skin provides a basal nociceptive tone. I found that administration of the 
P2Y1 antagonist in the hindpaw at baseline increased mechanical thresholds compared to vehicle 
treated mice (Figure 18). This result suggests that the P2Y1 receptor contributes a pro-nociceptive 
tone at baseline, which can be modulated by P2Y1 receptor antagonists. If tonic release of ATP is 
present and activates the P2Y1 receptor, then the P2Y12 and P2Y13 receptors should also be 
activated. I discovered that administration of P2Y12 and P2Y13 receptor antagonists in the 
hindpaw produced a mechanical hyperalgesia (Figure 18), which is expected if the receptors are 
tonically active given that P2Y12 and P2Y13 receptor activation would normally provide anti-
nociceptive drive. Hence, all three ADP receptors, P2Y12, P2Y12 and P2Y13, are active in basal 
conditions and contribute opposing effects on basal nociceptive tone. While my model would 
suggest the most direct way for this to occur is through keratinocyte-mediated ATP release onto 
afferents, there is a possibility that immune cells are also involved. Many immune cells express a 
wide array of purinergic receptors, including all three ADP receptors, and are capable of releasing 
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pro-inflammatory molecules as well. Therefore, it is possible that tonic ATP release from 
keratinocytes acts on immune cells, which then release substances to modulate nociceptors and 
produce the effects seen with my behavioral results.  
There are several reasons why immune cells involvement, while probable, is likely not the 
primary driver of my behavior effects. First, there is a question of the extent of immune cell 
recruitment occurs with injection of any agent into the hindpaw. Certainly, injection of the 
antagonists does not produce the hallmark signs of inflammation at the site: edema and redness. 
Second, the antagonists’ duration of action likely precludes an ongoing inflammatory response, 
should one have even occurred at the time of injection. Unlike with inflammatory models, such as 
CFA, the behavioral phenotype produced by ADP administration concludes by 24 hours post-
injection. While the acute duration of action of the agonists/antagonists does not exclude the 
possibility that an acute immune response occurred simultaneously, there does not seem to be a 
behavioral phenotype produced by the hypothetical inflammatory response. A conclusive answer 
to whether the behavioral effects I found with the ADP receptor antagonists are due to nociceptor 
or immune cell activity is not possible without the ability to selectively modulate nociceptor P2Y1, 
P2Y12 and P2Y13 receptor levels. However, despite this limitation, the result that peripheral 
blockade of the ADP receptors produced a significant behavioral phenotype lends support to the 
data demonstrating basal ATP release and establishes the importance of P2Y1, P2Y12 and P2Y13 
receptors in basal nociceptive tone. 
4.3.1 Future directions 
My results from chapter 3.0 characterized the signaling cascade of P2Y12 and P2Y13 receptors, 
demonstrating the ability of these receptors to inhibit nociceptive signaling in basal and 
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inflammatory states. Additionally, I revealed a novel technique to identify downstream targets of 
P2Y12 and P2Y13 signaling by using a PKA-specific protein phosphorylation antibody. Finally, 
I used a reporter for adenylyl cyclase activity, pCREB, to demonstrate the ability of P2Y12 and 
P2Y13 receptors to inhibit adenylyl cyclase-mediated signaling. Several questions remain 
regarding the P2Y12 and P2Y13 receptor function within dorsal root ganglion neurons.  
First, canonical Gi/o-coupled signaling indicates P2Y12 and P2Y13 receptors should inhibit 
adenylyl cyclases and voltage dependent calcium channels. Adenylyl cyclases are an important 
component for pro-inflammatory signaling and voltage dependent calcium channels contribute to 
cell hyperexcitability, both of which are critical in the pro-inflammatory response. While we have 
direct evidence of P2Y12 and P2Y13 receptor-mediated inhibition of adenylyl cyclase function, I 
did not conduct electrophysiology experiments in dorsal root ganglion neurons to assess the ability 
of P2Y12 and P2Y13 receptors to inhibit voltage dependent calcium channels. However, work 
from our lab has shown indirectly using calcium imaging that P2Y12 and P2Y13 receptor 
activation can attenuate calcium influx due to depolarizing high potassium solution application 
(Malin and Molliver, 2010). A logical next experiment would be to investigate the ability of P2Y12 
and P2Y13 receptors to directly inhibit voltage-dependent calcium channels in cultured dorsal root 
ganglion neurons using electrophysiology in basal and inflammatory states. This data would 
complement the adenylyl cyclase data from my thesis nicely and provide further evidence of the 
anti-nociceptive potential of P2Y12 and P2Y13 receptors.  
Second, I chose to group the two ADP-responsive Gi/o-coupled P2Y12 and P2Y13 
receptors together in my experiments. The primary goal of my thesis was to characterize the ADP 
responsive receptors and their signaling cascades, which involves investigating basal receptor 
function. As such, endogenous production of ADP, due to basal release or after injury, would 
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activate all receptors simultaneously and thus the actions of P2Y12 and P2Y13 are likely summed. 
Moreover, P2Y12 and P2Y13 receptors show significant overlap in expression within DRGs, 
making it more likely that ADP would act on both receptors similarly (Malin and Molliver, 2010). 
However, given that P2Y12 receptors are important in platelet function and would therefore 
produce side effects when activated for the treatment of pain, it would be beneficial to dissociate 
the P2Y12 and P2Y13 receptors in the future. Selective antagonists for each receptor do exist, 
which would allow me to test efficacy of P2Y12 and P2Y13 receptors separately in basal and 
inflammatory states using behavioral tests and adenylyl cyclase and protein phosphorylation 
assays. This set of experiments could reveal distinct roles for P2Y12 and P2Y13 receptors, in 
context- or dose-dependent manners.  
Third, while I was able to assess the general ability of P2Y12 and P2Y13 receptors to 
attenuate mechanical hyperalgesia, I was unable to directly contribute that to nociceptor activity 
because immune cells also express these receptors (Table 1). Using an ex vivo skin-nerve prep, 
where agents can be applied to the skin and the innervating nerves recorded from, would allow for 
a direct test of nociceptor involvement in P2Y12 and P2Y13-mediated effects (Jankowski et al., 
2012). Additional experiments using CFA-inflamed skin could also be conducted to establish the 
role of P2Y12 and P2Y13 receptors in attenuating inflammation-induced afferent excitability using 
the ex vivo prep. Finally, using siRNA to P2Y12 and P2Y13 receptors injected into the DRGs or 
developing transgenic mice with DRG-specific knockouts would also allow for a direct test of 
what tissue potentiates the effects of ADP administration.  
Finally, I used a general adenylyl cyclase activator, FSK, to examine P2Y12 and P2Y13 
receptor function. This works under the assumption that adenylyl cyclases are a single protein and 
not a family of isoforms and that they are expressed ubiquitously in tissue and activated by same 
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stimuli. However, there are nine isoforms of adenylyl cyclases and they all exhibit differing 
responses to Gi/o-coupled inhibition (Defer et al., 2000, Hanoune and Defer, 2001, Pinto et al., 
2008). Unpublished work from our lab has uncovered that the adenylyl cyclase 1 isoform (AC1) 
shows restricted expression in DRG neurons, primarily in non-IB4+ cells. AC1 is also strongly 
inhibited by the Gi/o-coupled pathway, whereas six of the remaining eight isoforms show weak or 
no response to Gi/o-coupled inhibition. Consequently, the effects of P2Y12 and P2Y13 activation 
might be restricted to a few or even one isoform of adenylyl cyclase and my technique of broadly 
activating all adenylyl cyclases could be diminishing the impact of P2Y12 and P2Y13 receptors. 
Given the importance of adenylyl cyclase as downstream targets for analgesics (i.e. NSAIDs) and 
within chronic pain models (Hucho et al., 2005, Joseph and Levine, 2010), targeting specific 
adenylyl cyclases alone or in conjunction with P2Y12 and P2Y13 agonists could be highly 
beneficial for the treatment of pain. 
4.4 BALANCE OF SIGNALING BETWEEN THE P2Y1 AND P2Y12/P2Y13 
RECPTORS IN BASAL AND INFLAMMATORY STATES 
Under physiological conditions, P2Y1, P2Y12 and P2Y13 receptors are likely to be activated 
simultaneously by ADP and the overall nociceptive tone is a summation of P2Y1 Gq-coupled and 
P2Y12/13 Gi/o-coupled effects. It is possible that distinct regulatory mechanisms for the 
antagonistic P2Y1 and P2Y12/13 receptors determine the overall nociceptive output of ADP 
signaling. There are several ways that the balance between these three ADP receptors can be 
shifted and/or integrated. 
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First, a shift in the expression of any of the three receptors would presumably skew the 
nociceptive tone towards the other receptors; an increase in expression of the pro-inflammatory 
P2Y1 would prime neurons to be in an excitable state, for example. Our previously published work 
lends support to this idea, as we demonstrated that during CFA-induced inflammation P2Y1 
mRNA decreases up to four days post-inflammation whereas P2Y12 and P2Y13 mRNA is 
increased (Malin and Molliver, 2010). An interpretation of this data is that P2Y1 mRNA is 
decreased during inflammation in order to attenuate further nociceptive signaling while P2Y12 
and P2Y13 mRNA is increased in order to provide anti-nociceptive drive; essentially, the neurons 
are attempting to decrease pro-nociceptive signaling by altering the balance of the three ADP 
receptors.  
Second, the integration of P2Y1 and P2Y12/P2Y13 receptor signaling could occur at the 
level of adenylyl cyclases. In Figure 2, I presented the canonical signaling cascades for g-protein 
coupled signaling, where Gs-coupled and Gi/o-coupled signaling interact through adenylyl cyclases 
while Gq-coupled signaling is distinct and separate. However, it has become evident that certain 
adenylyl cyclase isoforms can be modulated by calcium and/or PKC, both of which are 
downstream of the Gq-coupled signaling cascade (Defer et al., 2000, Hanoune and Defer, 2001). 
Interestingly, adenylyl cyclase isoforms are affected differently by calcium and PKCs, with 
adenylyl cyclase 1 (AC1) enhanced by calcium and PKCs and adenylyl cyclase 6 (AC6) inhibited 
by both (Sunahara and Taussig, 2002). Depending on which adenylyl cyclase is expressed by the 
dorsal root ganglion neurons, the outcome of GPCR signaling integration would vary widely. It is 
also possible that the inflammatory state could change the expression of various adenylyl cyclase 
isoforms to dampen pro-nociceptive signaling; if the AC6 isoform was upregulated, for example, 
all three ADP receptors would likely inhibit its function and attenuate pro-inflammatory signaling. 
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Extrapolating further, chronic injury states could be potentiated by an adenylyl cyclase isoform 
that is activated by Gq-coupled signaling and does not respond well to Gi/o-mediated inhibition.  
Additionally, the importance of adenylyl cyclase in producing the switch from acute to 
chronic pain has been well-documented in Jon Levine and colleagues’ hyperalgesic priming model 
(Hucho et al., 2005, Joseph and Levine, 2010), and in this model a molecule termed ‘Epac’ is 
responsible for a cAMP-to-PKC switch. Thus, there is cross-talk not only between the different 
GPCR signaling cascades onto adenylyl cyclases but adenylyl cyclases can potentiate signaling of 
other signaling cascade components (i.e. the Gq-coupled component PKC). Interestingly, Levine 
and colleagues found that a specific PKC isoform, PKCε, mediates this cAMP-to-PKC cross-talk 
in their hyperalgesic priming model and that the IB4+ population was critical for this process 
(Joseph and Levine, 2010). These results bring up the complex nature of studying signaling 
cascades, as context- and cell-dependent factors can drastically change which components within 
any given signaling cascades are involved.  
The notion that the relative balance of three ADP receptors, P2Y1, P2Y12 and P2Y13, can 
shift nociceptive tone is intriguing. The work presented in this thesis, as well within the pain 
literature, highlights the multifaceted nature of GPCR signaling and stresses the importance of 
studying these mechanisms in appropriate model systems and disease states. Future studies 
elucidating the signaling components of each of the ADP receptors and how they relate to one 
another in basal and inflammatory states would further our understanding of GPCR signaling and 
pain pathology.  
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4.5 NUCLEOTIDE SIGNALING WITHIN A BROADER CONTEXT 
Nucleotide signaling has been extensively studied since the role of nucleotides in nociception was 
first proposed in the late 1960s (Collier et al., 1966). Further investigation into nucleotide signaling 
brought up the exciting possibility that nucleotides could serve as critical transducers for 
communication between target tissue and nociceptors, demonstrating that the tissues innervated 
by nociceptors are not merely passive components but play an active role in nociceptive signaling 
(Burnstock, 1996, Burnstock, Knight et al., 2002, Birder et al., 2003, Shinoda et al., 2009, 
Takahashi et al., 2013). Tissues innervated by nociceptors, such as keratinocytes in the skin, 
urothelial cells in the bladder and epithelial cells of the colon, express a complement of purinergic 
receptors. The expression of these receptors contribute to the ability of the aforementioned non-
neuronal tissues to have a role in nociception (Burnstock, 2001b, Knight et al., 2002, Birder et al., 
2003, Shinoda et al., 2009, Burnstock et al., 2012, Birder and Andersson, 2013, Burnstock, 2014). 
Nociceptors also express a variety of metabotropic and ionotropic purinergic receptors that 
are capable of responding to ATP release; furthermore, nociceptors display an amazing complexity 
in the ATP metabolites they respond to. Enzymes located on the nociceptors themselves are 
capable of metabolizing ATP into numerous other nucleotides (Table 1), allowing for increasingly 
complex signaling to occur following simple ATP release. As it is clear that nucleotides play an 
important role in nociception, and work with purinergic receptor knockouts demonstrates that their 
absence cannot be compensated for; the justification for investigating nucleotide signaling in the 
context of pain is readily apparent.  
In my thesis work, I chose to explore ADP signaling because of ADP’s ability to act on 
both pro-nociceptive (P2Y1) and anti-nociceptive (P2Y12 and P2Y13) receptors within the same 
DRG neurons. The arrangement of having simultaneous activation of antagonistic receptors 
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subtypes raises broader questions regarding signal integration within the dorsal root ganglion 
during inflammation, not only for the ADP-responsive receptors but also for all of the receptors 
that have been implicated in nociception. In the case for the ADP-responsive receptors, there is 
some indication that adenylyl cyclases could be the points of signal integration and this could hold 
true for many metabotropic receptors as well. In the past few decades, the idea that GPCR signaling 
does not solely occur in three distinct canonical pathways (Figure 2), but rather involves a 
substantial deal of cross-talk, has been posited (Kawabe et al., 1994, Hucho et al., 2005). Hence, 
the output of GPCR signaling is not purely the direct pathways we have come to expect, but also 
new and unique pathways that are potentially critical for understanding the effects of chronic 
nociceptive signaling. How nociceptors integrate the multitude of nociceptive signaling cascades 
is vital if we are to truly understand the entire nociceptive machinery, from the target tissue to the 
central nervous system. 
It is clear within the pain field that development of new analgesics has been fraught with 
challenges, with remarkable data from animal models not translating to clinical benefit in patients. 
While the obvious explanation could be that animal models are not fully able to mimic human 
diseases, and therefore effectiveness of a potential therapeutic in animals is not a reliable predictor 
of human efficacy, another intriguing possibility is that we simply are not maximizing the 
information that can be gathered from animal models. As we are just beginning to discover, the 
integration point between multiple receptors is key to exploring this possibility, as it would allow 
us to comprehend the effects of the total inflammatory state better than single signaling cascades 
or receptor targets alone. 
Nucleotide signaling provides an indispensable model system to study signal integration in 
this case because of the ability of a single nucleotide, ATP, to activate a whole host of signaling 
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cascades. The sheer number of components that are activated as a result of ATP release creates a 
signaling complexity that can mimic, in some part, what occurs in a broader inflammatory state. 
Thus, nucleotide signaling and the study of how that signaling is integrated provides a template by 
which other signaling systems within the dorsal root ganglion neurons can be explored. 
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5.0  CONCLUSIONS 
Purinergic P2Y receptors have been implicated in peripheral inflammatory pain, however there is 
little information in the field regarding their signaling cascades. The work contained in this 
dissertation characterized the three ADP-responsive purinergic receptors P2Y1, P2Y12 and P2Y13 
and their signaling cascades, downstream targets of signaling during inflammation and effects of 
receptor activation on behavior. We found that the effects of P2Y1 receptor activation on protein 
phosphorylation and pain behavior are mediated primarily through the conventional PKC isoform, 
PKCα. P2Y12 and P2Y13 receptors displayed tonic activity at baseline, underscoring their 
importance for establishing basal nociceptive tone. Activation of P2Y12 and P2Y13 receptors 
significantly attenuated hypersensitivity induced by adenylyl cyclase activation, highlighting the 
importance of P2Y12/P2Y13 receptors as potential analgesics. Taken together, these data uncover 
the critical signaling components of the three ADP receptors, P2Y1, P2Y12 and P2Y13 in dorsal 
root ganglion neurons and emphasize their contribution to basal nociceptive tone and importance 
in modulating inflammatory pain.
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APPENDIX 
ACTIVITY-DEPENDENT REGULATION OF P2Y12 AND P2Y13 BY GRKS 
 
Objective: Establish the importance of GRKs in dorsal root ganglion cells in order to determine 
whether P2Y12 and P2Y13 receptors undergo activity-dependent GRK-mediated modulation. 
Background: G protein-coupled receptor kinases (GRKs) are an important auto-regulatory 
mechanism to curb chronic G-protein coupled receptor (GPCR) activation. GRKs bind to and 
phosphorylate activated GPCRs, resulting in a cascade that leads to receptor internalization. The 
GRK family member GRK2 is required for the activity-dependent internalization of P2Y12 
receptors in heterologous cell systems and without GRK2, P2Y12 remains at the membrane despite 
ongoing activation (Hardy et al., 2005, Hoffmann et al., 2008).  Little is known about P2Y13 
receptor regulation but P2Y12 and P2Y13 share a high sequence homology, which raises the 
possibility P2Y12/13 receptors are both regulated by GRKs. 
 
Introduction 
 
Most G-protein coupled receptors (GPCRs) undergo activity-dependent desensitization as a way 
to attenuate ongoing signaling. GPCR kinases (GRKs) and protein kinase C (PKC) mediate a large 
portion of GPCR desensitization (Pitcher et al., 1992, Freedman and Lefkowitz, 1996, Krupnick 
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and Benovic, 1998, Komori et al., 1999, Moore et al., 2007, Dumas and Pollack, 2008, Hoffmann 
et al., 2008, Kelly et al., 2008). GRKs phosphorylate activated GPCRs, leading to β-arrestin 
mediated internalization of the receptor (Benovic et al., 1987, Lohse et al., 1990, Krupnick and 
Benovic, 1998, Kohout and Lefkowitz, 2003). GRK2 is a member of the larger serine/threonine 
GRK family of kinases and possesses an extended C-terminal region containing a pleckstrin 
homology domain (PH) (Gainetdinov et al., 2004). The PH domain contains binding sites for Gβγ-
subunits and phosphatidylinositol lipids located on the membrane. GPCR activation directly 
recruits GRK2 to the membrane via this PH domain; GRK2 is activated at the membrane and is 
then able to phosphorylate GPCRs. The phosphorylated GPCRs then undergo activity-dependent 
internalization from membrane. GRKs can also modulate GPCR function in a phosphorylation-
independent manner by binding the Gβγ-subunits that are a part of the G-protein complex on 
GPCRs (Gainetdinov et al., 2004). Interestingly, it is thought that Gi/o-coupled receptors inhibit 
voltage dependent calcium channel function via Gβγ-subunits (De Waard et al., 1997, Zamponi et 
al., 1997). Thus, a reduction in GRK2 would both prevent activity-dependent internalization of 
GPCRs and allow for enhanced Gβγ-subunit mediated effects. Opioid receptors undergo both 
GRK2 and PKC-dependent desensitization (Kramer and Simon, 1999, Bohn et al., 2002). 
Therefore, even if reduced GRK2 expression promotes opioid receptor localization at the 
membrane, opioid receptors can still show activity-dependent desensitization via PKC. 
Unlike with opioid receptors, GRK2 is solely responsible for activity-dependent 
internalization of P2Y12 receptors in heterologous cell systems (Hardy et al., 2005, Mundell et al., 
2006c, Hoffmann et al., 2008)  Without GRK2, P2Y12 receptors maintain their responses to ADP 
indicating that other desensitization mechanisms, if present, do not play a major role in attenuating 
activity-dependent P2Y12 responses (Hardy et al., 2005, Mundell et al., 2006c, Hoffmann et al., 
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2008). The other ADP activated purinergic receptor, P2Y1, is primarily desensitized through PKC 
mechanisms and not GRK2 (Hardy et al., 2005, Mundell et al., 2006c). Therefore, at least within 
the ADP signaling cascade, GRK2 regulates only the anti-nociceptive P2Y12 receptor. The ability 
of GRK2 to regulate P2Y13 has not been tested in heterologous systems or elsewhere; given that 
both P2Y12 and P2Y13 receptors are activated by the same agonist and share a high sequence 
homology, there is a strong possibility they are under similar regulatory control. The specificity of 
GRK2 for the P2Y12 receptor over the P2Y1 receptor is an extremely important distinction 
because a reduction in GRK2 would shift the ADP signaling balance strongly in favor of anti-
nociceptive signaling.  
In the carrageenan inflammatory model, a dose of carrageenan that produces chronic 
inflammatory hyperalgesia also produces a 35% reduction in GRK2 expression as determined by 
immunohistochemistry (Eijkelkamp et al., 2010). GRK2 heterozygous knockout mice display 
prolonged and enhanced inflammatory hyperalgesia in response to a variety of mediators such as 
prostaglandin and carrageenan (Eijkelkamp et al., 2010, Ferrari et al., 2012). This effect is thought 
to be mediated by a direct modulation of signaling components downstream of the Gs-coupled 
receptor, including adenylyl cyclase, as opposed to changes in receptor internalization (Eijkelkamp 
et al., 2010, Ferrari et al., 2012). Therefore, a reduction in GRK2 expression is exclusively studied 
in animal models for its ability to enhance the inflammatory process. No studies to my knowledge 
exist that attempt to exploit the reduced GRK2 expression in order to drive anti-nociceptive 
signaling.  
GRK3 is a member of the GRK family and has also been implicated in pain (Terman et al., 
2004, Xu et al., 2004). GRK3 has primarily been studied for its ability to modulate opioid analgesic 
tolerance, and very few studies exist outside of that literature regarding GRK3 and pain. Given the 
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sequence homology between GRK2 and GRK3, it is possible that both GRKs can modulate P2Y12 
and P2Y13 receptors and further analysis of their role in ADP-mediated signaling is warranted 
(Watari et al., 2014). 
This study characterized the effects of GRK2 and related family member GRK3 
modulation on P2Y1, P2Y12 and P2Y13 receptor-mediated effects.  
 
METHODS 
 
Animals 
All experiments were conducted on adult male wild type C57BL6 or GRK3KO mice (The 
Jackson Laboratory, Stock No: 012431). Mice were housed in group cages with a maximum of 4 
per cage in a temperature-controlled environment (20.5 °C). They were given food and water ad 
libitum and maintained on a 12:12 hour light-dark cycle. All studies were carried out in 
adherence to the guidelines of the Institutional Animal Care and Use Committee of the 
University of Pittsburgh as well as the NIH Guide for the Care and Use of Laboratory Animals. 
 
Western blot analysis of carrageenan-inflamed dorsal root ganglion neurons 
Mice glabrous hindpaw were injected with λ-carrageenan (2% w/v; Sigma-Aldrich) in saline and 
6 days post-injection, L2-L5 dorsal root ganglion neurons were harvested. Animals were perfused 
with ice-cold HBSS (pH 7.4) and DRGs placed into snap cap tubes on dry ice. Pierce IP lysis 
buffer (Thermo Fisher Scientific) was added to the tubes and the DRGs were lysed using a 
motorized homogenizer. Lysed protein was loaded onto precast protein gels (Thermo Fisher 
Scientific Precise protein gel) and the samples run at 111V for 25 min and 140V for at least 20 
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min in ice-cold 1X PAGE buffer. The protein was transferred on to membrane paper and 
transferred in ice-cold buffer for 1.5 hours at 40V. The membrane was rinsed with 1X PBS 2 times, 
for 10 minutes each. The membrane was then blocked with 1X PBS+5%BSA+0.05% Tween-20 
for 1 hour at room temperature. GRK2 primary antibody was diluted into the blocking buffer and 
incubated overnight at 4C while shaking. The next day, the membrane was washed with 1X 
PBS+0.1% Tween-20 for 10 minutes each, 3 times total, and then incubated with secondary 
antibody for 1 hour at room temperature while shaking. Fluorescence images were acquired using 
a FluoChem Q blot imager (Cell Bioscience, Santa Clara CA) and analyzed by AlphaView. To 
analyze the protein levels, fluorescence intensity was calculated for each band of interest and 
normalized according to loading controls. The vehicle (6d) versus carrageenan (6d) fluorescent 
intensity levels were compared using an unpaired t-Test. 
 
Thermal and mechanical behavioral testing 
Behavioral data were collected in the Rodent Behavior Analysis Core of the University of 
Pittsburgh Schools of Health Sciences. Mice were placed in individual Plexiglass chambers on a 
mesh or glass platform and acclimated for 60 min at room temperature for 3 days. See Figure 13 
for graphic representation of mechanical testing described below. 
Standard von Frey testing: Hindpaw withdrawal frequencies to von Frey mechanical stimulation 
(vF #3.61, equivalent to 0.4g force) were measured as the number of withdrawals out of 10 trials 
per mouse, with 10 withdrawals out of 10 corresponding to a 100% withdrawal frequency. 
Responses were recorded at 0 (baseline), 30, 60, 120 min and 24 hr after treatments. Drug solutions 
were made in saline immediately before use for each experiment and experimenter was blinded to 
the conditions. The following drugs were purchased from Tocris: 2methylthioadenosine 
 117 
diphosphate (2MeSADP, P2Y12/13 receptor agonist), AR-C66096 (selective P2Y12 antagonist) 
and MRS2211 (selective P2Y13 antagonist) were all used at 10nmols/10µl. The GRK2 inhibitor 
was purchased from EMD Millipore (catalog number: 182200) and used at 10nmols/10µl.  
Hargreaves thermal testing: Hindpaw withdrawal latency to a radiant heat light source with 
integral timer activated by an electric trigger was measured (IITC, 15% intensity). Flinching or 
lifting of the paw was considered a withdrawal. Responses were recorded at baseline and up to 48 
hours post-FSK administration. The average withdrawal latency was the mean of 3 trials/mouse 
and 20s withdrawal latency cutoff was used to prevent tissue damage. Drug solutions were made 
in saline immediately before use for each experiment and experimenter was blinded to the 
conditions. Forskolin (Tocris) was used at 10μM and 10μL amount was injected in the glabrous 
hindpaw.  
 
Statistical analysis 
Data for the behavioral experiments are presented as mean ± standard error of the mean (SEM). 
Statistical analyses were performed using two-way repeated measure analysis of variance 
(ANOVA), with the repeated measure being time, followed by Bonferroni post hoc test. All data 
were analyzed using SigmaPlot (version 12.0, Systat Software Inc.). 
 
RESULTS 
 
Carrageenan-induced inflammation decreases GRK2 protein 
GRK2 protein levels were analyzed in DRGs from glabrous hindpaw saline treated and 
carrageenan treated mice 6 days post-injection. GRK2 protein levels decreased 54.8% in 
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carrageenan treated animals compared to saline treated mice (saline FAU 520.06 ± 87.4 versus 
Carrageenan FAU 235.1550 ± 77.6, n=3 animals/condition). The decrease in GRK2 protein levels 
could facilitate nociceptive signaling, as GRK2 is a major regulator for GPCR internalization.  
Figure 19: GRK2 protein is decreased following carrageenan-induced inflammation. 
Administration of 2% carrageenan (w/v) into the hindpaw produced over a 50% decrease in GRK2 
protein levels compared to vehicle treated mice (saline FAU 520.06 ± 87.4 versus Carrageenan 
FAU 235.1550 ± 77.6). Data is reported as mean ± standard error of the mean (SEM) of arbitrary 
fluorescence values (FAU) from n=3 animals. Statistical analysis was done using a student’s t test, 
asterisk (*) indicates one tailed P-value < 0.05.  
GRK2 modulates 2MeSADP- mediated mechanical hyperalgesia 
Hindpaw administration of P2Y1, P2Y12 and P2Y13 receptor agonist 2MeSADP (10nmols/10μL) 
produces a robust mechanical hyperalgesia (57 ± 13% withdrawal latency at 30 min peak and 51 
± 6.22% at 60 min) that returns to baseline at 24 hours post-injection. Co-injection of 2MeSADP 
with the GRK2 inhibitor (10nmols/10μL) attenuates this hyperalgesia at 30 min and 60 min post-
injection (22 ± 7.57% at 30 min and 39.0 ± 6.74% at 60 min). All groups return to baseline 24 
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hours post-injection. The ability of the GRK2 inhibitor to attenuate 2MeSADP-mediated 
mechanical hyperalgesia points to a critical role for GRK2 in regulating the ADP receptors.  
 
 
 
Figure 20: GRK2 inhibition attenuates P2Y1 receptor-mediated mechanical hyperalgesia. 
Administration of 2MeSADP (10nmols/10μL) produced a robust mechanical hyperalgesia that is 
attenuated with GRK2 inhibition (10nmols/10μL) at 30 min and 60 min post-injection.  Asterisks 
(*) indicate P<0.05 (± SEM) versus vehicle and pluses (+) indicate P<0.05 2MeSADP vs. GRK2 
(-) + 2MeSADP as determined by two way ANOVA RM, Post hoc: Bonferroni. N=10 
animals/condition.  
 
GRK3KO mice display prolonged mechanical hyperalgesia in response to adenylyl cyclase 
activation 
Administration of the adenylyl cyclase activator, forskolin (FSK, 10μM), in wildtype and 
GRK3KO mice produce a substantial decrease in paw withdrawal latency to a radiant heat source 
at 60 min post- injection (WT: baseline 100 ± 3.46% versus FSK-treated 62.64 ± 3.97%; 
GRK3KO: baseline 100 ± 10.72% versus FSK-treated 68.89 ± 7.29%). In WT mice, the FSK-
induced thermal hyperalgesia resolved by 24 hours post-injection, whereas GRK3KO mice display 
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a significant hyperalgesia that does not resolve by 48 hours post-injection (WT: baseline 100 ± 
3.46% versus FSK-treated 89.35  ± 6.72%; GRK3KO: baseline 100 ± 10.72% versus FSK-treated 
68.62  ± 7.96%).. Baseline paw withdrawal latencies were not different between wildtype and 
GRK3KO mice, suggesting basal thermal processing is intact at the behavioral level.  
Figure 21: Characterization of FSK-induced thermal sensitivity in GRK3KO mice. 
FSK administration (10μM, Tocris), produces a decrease in paw withdrawal latency to a radiant 
heat source in Wildtype (black line, n=10 mice) and GRK3KO (red line, n=5 mice) mice. 60 min 
post-FSK injection, both wildtype and GRK3KO mice display significant thermal hyperalgesia, 
with GRK3KO mice maintaining a hyperalgesic state 48 hours post-injection whereas wildtype 
mice return to basal levels by 24 hours post-injection. Raw values are measured in seconds to paw 
withdrawal from the radiant heat source. Asterisks (*) indicate p<0.05 as compared to baseline 
values, determined by Two Way ANOVA with Bonferroni post-hoc. 
CONCLUSIONS 
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G-protein receptor kinases 2 and 3 (GRK2 and GRK3) have both been implicated in pain (Terman 
et al., 2004, Xu et al., 2004, Eijkelkamp et al., 2010, Ferrari et al., 2012, Wang et al., 2013). As 
kinases that regulate GPCR internalization, GRK2 and GRK3 have the potential to facilitate 
nociception by promoting internalization of anti-nociceptive receptors such as the opioids, or 
attenuating nociception by promoting internalization of pro-nociceptive receptors. Additionally, 
changes in the relative expression of GRKs can have a significant impact on nociceptive 
processing as demonstrated in inflammatory pain models by several groups (Eijkelkamp et al., 
2010, Ferrari et al., 2012, Wang et al., 2013). 
 In order to further characterize GRK2 and GRK3, I first determined the effect of 
carrageenan-induced inflammation on GRK2 levels. I found a substantial decrease in GRK2 
protein 6 days post-carrageenan injection. Next, I tested the ability of GRK2 to modulate ADP 
receptors using ADP-induced mechanical hyperalgesia. I discovered that GRK2 inhibition 
temporarily attenuates ADP-induced mechanical hyperalgesia, indicating the lack of GRK2 might 
prevent activity-dependent P2Y12/P2Y13 receptor internalization allowing these receptors to 
exert greater anti-nociceptive drive. Finally, GRK3KO mice display prolonged FSK-induced 
thermal hyperalgesia that does not resolve for at least 48 hours  unlike WT controls, demonstrating 
the ability of GRK3 to modulate nociceptive processes.  
These results suggest a role for both GRK2 and GRK3 in peripheral hypersensitivity. 
Further investigation is necessary to determine the mechanism by which GRK2 and GRK3 regulate 
P2Y12 and P2Y13 receptors.  
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